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θησαύρισμα. Μάρτυς ένδοξε, Χριστόν τον Θεόν ικέτευε, δωρήσασθαι ημίν το μέγα έλεος.’’ 
 
(Απολυτίκιο Αγίου Παντελεήμων) 
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 ABBREVIATIONS 
 
WHO : World Health Organization 
 
RBCs : Red Blood Cells 
 
ACTs : Artemisinin based Combination Therapies 
 
ART : artemisinin 
 
DHA : dihydroartemisinin 
 
AS : Artesunate 
 
ATH : Artemether 
 
ARTs: Artemisinin derivatives (DHA, AS and ATH) 
 
CQ: Chloroquine 
 
MQ : Mefloquine 
 
PPQ : Piperaquine 
 
LMF : Lumefantrine 
 
AMQ : Amodiaquine 
 
K13 : Kelch 13 propeller 
 
SYK : Spleen Tyrosine Kinase 
 
IC50 : Inhibitory Concentration of 50% 
 
P. falciparum : Plasmodium falciparum 
 
HMC : Hemichromes 
 
hRBCs : hemicromes in Red blood cells 
 
Hb : Hemoglobin 
 
metHb : methemoglobin 
 
Trx : thioredoxin 
 
Digestive vacuole : DV 
 
Ferriprotoporphyrin IX : FP 
 
RNS : Reactive nitrogen species 
 
SOD :  superoxide dismutase 
 
Fig. : Figure 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
SUMMARY 
 
The current therapy used for the treatment of malaria is based on the administration of a series of 
artemisinin derivatives combined with some quinolinic antimalarial drugs that, due to their 
prolonged action, compensate for the short life of artemisinins. Many of which are affected by 
diffuse resistance. The efficacy of the artemisinin combined therapies (ACTs) therefore rely on the 
very fast action of artemisinins, however the available ACTs are designed to compensate for its 
incomplete antiplasmodial effect. The combinations aimed to synergize the action of artemisinins 
are not yet available and this opportunity could assist in counteracting the emerging resistance to 
artemisinin. 
 
The aim of this study is to propose new antimalarial combinations utilising Syk inhibitors and 
artemisinins (ARTs). The in vitro experiments showed great synergy between all the tested Syk 
inhibitors and artemisinins, especially between P505-15 and DHA with a combination index of 0,42 
at 24 hours of incubation. In fact, Syk inhibitors enhance artemisinins’ anti-plasmodial activity 
leading to a 3-5 fold decrease of their IC50 values. Furthermore we investigated the mechanism of 
action between Syk inhibitors and artemisinins in P. falciparum strains. 
 
The mechanism of action of artemisinins is basically unknown but its efficacy is known to rely on 
the availability of reactive iron which is needed to generate a pharmacologically active radical. 
Erythrocytes appear to be ideal candidates for the activation of artemisinin because of the 
exceptionally high iron content. However, no free iron is practically available in erythrocytes and 
the iron caged in hemoglobin is not useful for catalyzing the artemisinin activation. It has already 
been described that hemichromes are spontaneously formed in parasitized erythrocytes and band 3 
becomes heavily phosphorylated from the earlier stages of parasite development. It is plausible that 
denatured forms of hemoglobin that are formed in parasitized erythrocytes may provide the reactive 
iron required for artemisinin activation, but direct evidence is unavailable. 
 
In the present study, we observed that Syk inhibitors determine a massive accumulation of 
hemichromes in the parasitized erythrocytes. Hemichromes may be responsible for the activation of 
artemisinin after reduction to Fe
II
 (artemisinin being insensitive to FeCl
3
 or hemichromes in 
absence of RBC). Hence, an accumulation of Fe
III
 via accumulation of hemichromes induced by 
Syk inhibitors would potentiate the artemisinin activity. 
 
In conclusion, considering their demonstrated tolerability, Syk inhibitors represent a new class of 
antimalarial drugs that possess a unique mechanism of action on a non-parasite target. Furthermore, 
 
7 
should not lead to the selection of resistant strains and may therefore represent a strategic partner 
drug for artemisinin therapies for counteracting artemisinin resistance. 
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ABSTRACT 
 
 
The primary objective of malaria treatment is to eradicate the disease, which involves rapid and 
complete elimination of the Plasmodium parasite from the patients’ blood. Artemisinin combination 
therapies (ACTs) are the mainstay of recommended treatment for P. falciparum malaria and as no 
alternatives to artemisinin derivatives are expected to enter the market for several years, their 
efficacy must be preserved. Unfortunately, the resistance to ACTs, is a major thread for the control 
and elimination of malaria due to P. falciparum. The need for new antimalarial drugs is more urgent 
than ever before, with emerging strains of the parasite now showing resistance against the best 
available drugs. Recently it has been demonstrated that Syk inhibitors represent a new class of 
antimalarial drugs which suppress merozoite egress by inhibiting the host target, a factor that cannot 
be mutated by the parasite to evolve drug resistance. In this study, our aim is to evaluate the in vitro 
combination activity of Syk inhibitors with artemisinins and understand their mechanistic 
interaction. The results showed a high synergistic combination activity between all tested Syk 
inhibitors with artemisinins against P. falciparum. The combination index analysis indicated the 
following Syk inhibitors as the most synergistic with Artemisinins: P505-15, R406 and Imatinib. 
Furthermore, we observed that Syk inhibitors produce a massive accumulation of hemichromes in 
the parasitized erythrocytes, this in turn triggers the activation of artemisinins and causes a marked 
synergistic effect when administered in combination. The synergic effect of Syk inhibitors is based 
on a novel mechanism of action acting selectively on the parasitized erythrocytes which allows the 
artemisinins to be activated quicker and more efficiently. The concentrations of Syk inhibitors 
needed to synergize artemisinins is 5-20 fold lower than the IC50 measured as a direct effect on 
parasite growth. These concentrations correspond to very well tolerated dosages and can be rapidly 
reached after oral administration. In conclusion, our results potentially suggest Syk inhibitors as a 
strategic class of partner drugs for a new ACT. 
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INTRODUCTION 
 
 
 
 
1.1. Chapter Synopsis 
 
 
The chapter begins with a brief background on the discovery and the history of Malaria, the 
lifecycle of Plasmodium, their pathophysiology and the effects of the disease. In addition, the 
oxidative alterations in host induced by Plasmodium are going to be presented. 
 
Since the objective of this thesis is the proposal of new antimalarial combinations, it’s important to 
analyze the principle antimalarials of this decade and the reason why WHO chose to use them in 
combination. Furthermore, the factors of the antimalarial drug resistance and specifically the 
artemisinin resistance are going to be described. 
 
Afterwards, an overview of the RBC modifications in pro-oxidant mutations (Band 3 tyrosine 
phosphorylation and Hemichromes release) will be discussed. Also, the methodologies for double 
and triple combinations will be analyzed. At the end of the chapter, Syk inhibitors as new potential 
antimalarial drugs and their hypothetical mechanism of action in parasitized red blood cells will be 
presented. 
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1.2. Background of Malaria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Anopheles, Entrance of parasites into mosquito after 
meal and production of sexual forms, gametes (1). Following 
formation of gametes in zygote (2) and maturation into ookinete  
(3). Representation of ookinete’s penetration into midgut’s 
membrane and the formation of oocyste (4) capable to produce 
thousand sporozoites (5). 
 
Malaria or a disease resembling malaria 
has been noted for more than 4,000 years. 
From the Italian for "bad air," mal'aria has 
probably influenced to a great extent 
human populations and human history. 
The early Greeks were also aware of the 
characteristic poor health and malarial 
fevers seen in people living in 
waterlogged places. Nowadays, Malaria 
remains one of the most important 
parasitic diseases. In 2016 were estimated 
429 000 malaria deaths (range 235 000 – 
639 000) worldwide. Most of these deaths 
 
occurred in the African Region (91.8%), followed by the South-East Asia Region (6.1%) and by the 
eastern Mediterranean region (2.1%)
2
. Children under 5 are particularly susceptible to malaria 
illness, infection and death. In 2015, malaria killed an estimated 303 000 under-fives globally, 
including 292 000 in the African Region. Between 2010 and 2015, the malaria mortality rate among 
children under 5 fell by an estimated 35%. Nevertheless, malaria remains a major killer of under-
fives, claiming the life of 1 child every 2 minutes. Specifically, malaria is a disease caused by 
Plasmodium spp, which are microscopic protozoa of the phylum Apicomplexa. P. falciparum, P. 
vivax, P. malariae and P. ovale are the human malaria species. Among the four species, 
Plasmodium falciparum represents the most pathogenic
3
 with the highest rates of complications and 
mortality
4
. Next chapters are going to describe the life cycle, Pathophysiology and Diagnosis of 
Malaria. 
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1.2.1. Life cycle of Malaria parasites 
 
The life cycle of Plasmodium (Fig.3) is 
similar to several other species in the 
Haemosporidia. All the Plasmodium 
species causing malaria in humans are 
transmitted by mosquito species of the 
genus Anopheles (Fig.1). The infection 
starts when an infected mosquito releases 
sporozoites into the skin of a human during 
a blood meal. The sporozoites travel to the 
liver, where they enter hepatocytes and 
subsequently divide for approximately 10 
days, after which they differentiate into 
merozoites. At the end of their 
developmental process in the liver, 
Plasmodium parasites differentiate into 
infective merozoites
5
. 
 
 
 
 
Figure 2. The intraerythrocytic cycle of Plasmodium 
 
Eventually, these liver merozoites are released into the lung capillaries, where they reach the 
bloodstream and begins the blood-stage of infection. Inside erythrocytes (Fig.2), the parasite 
undergoes a 48-hour-long developmental process that starts with the ring stage (0–24hours), 
followed by DNA replication and parasite growth during the trophozoite stage (24–36 hours) and, 
ultimately, the schizont stage (36–48 hours), during which infectious merozoites are formed. A 
small percentage of the parasites undergo differentiation into gametocytes (not shown), which can 
be taken up by a mosquito during a blood meal and can then mate inside the mosquito gut, export of 
parasite proteins also occurs at this stage. During the intracellular stages in the vertebrate host, the 
parasite actively remodels the host erythrocyte. An outline of the export pathway of a protein is 
shown, starting with secretion through the secretory pathway (initiating in the endoplasmic 
reticulum) into the parasitophorous vacuole (PV). Transmembrane domain-containing proteins may 
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be transported through vesicle-like structures, exported proteins, including Plasmodium falciparum 
erythrocyte membrane protein 1 (PfeMP1), are part of the knobs and the Maurer’s clefts6. 
 
1.2.2. Pathophysiology and Diagnosis of Malaria  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Life cycle of Malaria parasite at Mosquito, Human liver and Blood stages. (CDC) 
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Malaria is caused by the direct effects of parasitized red cells and destruction by the asexual 
parasites, and the host’s reaction to this process. In P. falciparum blood-stage infections, 
protuberances appear on the surface of the erythrocyte 12–15 hours after cellular invasion. These 
membrane «knobs» extrude a high molecular weight, strain-specific adhesive protein (PfEMP1) that 
mediates cytoadherence, or attachment of the parasitized erythrocyte to endothelial surface 
receptors in veins and capillaries, resulting in the sequestration of parasitized erythrocytes in these 
vessels. Under febrile conditions, which enhance PfEMP1 expression, cytoadhesion begins at 
approximately 12h of parasite development. Febrile temperatures induce cytoadherence of ring-
stage Plasmodium falciparum-infected erythrocytes
7
. 
 
Once adherent, the infected red cells do not detach until schizont rupture. There is some ring-stage 
adherence via separate mechanisms. The infected erythrocytes adhere to the vessel walls and 
eventually cause heterogeneous blockage of the microcirculation. Parasitized erythrocytes may also 
adhere to each other (agglutination) and to uninfected erythrocytes (rosetting). These adherence 
processes are central to the pathogenesis of falciparum malaria, resulting in the sequestration of red 
cells containing mature parasites in vital organs (including the brain), where they interfere with 
microcirculatory flow and metabolism and the function of vascular endothelium. Only the younger 
ring form P. falciparum parasites circulate in falciparum malaria, and so the peripheral parasite 
count may substantially underestimate the actual total parasite biomass. As the intraerythrocytic 
parasites mature, they make the infected red cells more spherical and rigid.
8 
1.2.2.1. Diagnosis of uncomplicated Malaria 
 
The signs and symptoms of malaria are non-specific. Malaria is suspected clinically primarily on 
the basis of fever or a history of fever. No combination of signs or symptoms that reliably 
distinguishes malaria from other causes of fever exists. In this way, diagnosis based only on clinical 
features has a low specificity and results in overtreatment. The focus of malaria diagnosis should be 
to identify patients truly suffering from malaria, to guide rational use of antimalarial medicines. In 
malaria-endemic areas, malaria should be suspected in any patient presenting with a history of fever 
or temperature 37.5 °C and no other obvious cause. In areas in which malaria transmission is stable, 
malaria should also be suspected in children with palmar pallor or a haemoglobin concentration of 
<8 g/dL. In settings where the incidence of malaria is very low, parasitological diagnosis of all 
cases of fever may result in considerable expenditure to detect only a few patients with malaria. In 
these settings, health workers should be trained to identify patients who may have been exposed to 
malaria (e.g. recent travel to a malaria-endemic area without protective measures) and have fever or 
a history of fever with no other obvious cause, before they conduct a parasitological test. 
 
15 
In all settings, suspected malaria should be confirmed with a parasitological test. The results of 
parasitological diagnosis should be available within a short time (< 2 h) of the patient presenting. In 
settings where parasitological diagnosis is not possible, a decision to provide antimalarial treatment 
must be based on the probability that the illness is malaria. The benefit of parasitological diagnosis 
relies entirely on an appropriate management response of health care providers. Light microscopy 
and immunochromatographic RDTs are the two methods used routinely for parasitological 
diagnosis of malaria. Both must be supported by a quality assurance program. Antimalarial 
treatment should be limited to cases with positive tests, and patients with negative results should be 
reassessed for other common causes of fever and treated appropriately. In almost all cases of 
symptomatic malaria, examination of thick and thin blood films by a competent microscopist will 
reveal malaria parasites. Malaria RDTs should be used if quality-assured malaria microscopy is not 
readily available. RDTs for detecting PfHRP2 can be useful for patients who have received 
incomplete antimalarial treatment, in whom blood films can be negative. This is particularly likely 
if the patient received a recent dose of an artemisinin derivative. If the initial blood film 
examination is negative in patients with manifestations compatible with severe malaria, a series of 
blood films should be examined at 6-12h intervals, or an RDT (preferably one detecting PfHRP2) 
should be performed. If both the slide examination and the RDT results are negative, malaria is 
extremely unlikely, and other causes of the illness should be sought and treated. In patients with 
suspected severe malaria and in other high-risk groups, such as patients living with HIV/AIDS, 
absence or delay of parasitological diagnosis should not delay an immediate start of antimalarial 
treatment. At present, molecular diagnostic tools based on nucleic-acid amplification techniques 
(e.g. loop-mediated isothermal amplification or PCR) do not have a role in the clinical management 
of malaria. Where P.vivax malaria is common and microscopy is not available, it is recommended 
that a combination RDT be used that allows detection of P.vivax (pLDH antigen from P.vivax) or 
pan-malarial antigens (Pan-pLDH or aldolase)
9
. 
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1.2.2.2. Diagnosis of severe Malaria 
 
 
Severe malaria is clinically similar to other severe febrile illnesses. Each clinical syndrome of 
severe malaria (coma, severe anaemia, acidosis) can have other causes (meningitis, sickle cell 
disease, septicaemia). Obtaining a parasitological diagnosis does not resolve the diagnostic 
problem, especially in high transmission areas, where asymptomatic parasitemia is common and 
may be incidental in any severe illnesses
10
. 
 
Overdiagnosis constitutes another possibility in countries where malaria is common, diverting 
attention from other infectious causes of severe febrile illness. Overdiagnosis of malaria, which is 
commonly due to neglect of a negative blood film or to failure to obtain a blood film or rapid 
diagnostic test (RDT), has been shown to contribute to mortality. A parasitological diagnosis should 
be obtained whenever possible, but the relevance of parasitaemia to the current illness must always 
be considered carefully. In the absence of diagnostic facilities, antimalarial treatment should not be 
delayed if the patient is severely ill. Yet, it should be started based on a clinical suspicion while 
other diagnoses are also considered. Microscopy remains the reference standard for the diagnosis of 
falciparum malaria, but this requires the availability of a good microscope, significant technical 
skills, good-quality reagents and clean slides. The diagnostic quality of microscopy is very variable 
in routine hospitals in sub-Saharan Africa
11
. 
 
 
1.2.3. Oxidative alterations in the host induced by Plasmodium 
 
 
It has been shown that oxidative stress is related to a protective role in malaria patients, as possible 
agents capable of destroying the Plasmodium. Thus, H2O2 and O2•− can operate independently as 
cytotoxic agents or form other toxic molecules, including radical OH•, hypochlorous acid (HOCl) 
and peroxynitrite (ONOO−) in the presence of NO. In fact, it is generally accepted that ROS, 
including O2•− and ONOO−, can destroy the parasite intraerythrocytically. Specifically, in response 
to infection caused by Plasmodium parasites, the natural host defense mechanism is activated with 
the involvement of phagocytes (macrophages and neutrophils). These, in turn, generate large 
amounts of ROS and RNS, causing an imbalance between the formation of oxidizing species and 
the activity of antioxidants. This imbalance is what triggers oxidative stress, which is an important 
 
 
 
17 
mechanism of human hosts in response to infections and, in the case of malaria, can lead to the 
death of the parasites. 
 
In vitro studies have demonstrated the ability of oxidative stress to promote the killing of parasites. 
Incubation of Plasmodium yoelii species in the presence of glucose and glucose oxidase-generated 
H2O2, a reactive oxygen species, capable of killing the parasite. Likewise, when incubated in the 
presence of xanthine and xanthine oxidase, it generated free radical superoxide (O2•−) and a 
subsequent burst of other oxidative products, with consequent destruction of parasites
12
. 
 
Finally, there are biomarkers to indicate oxidative stress in malaria, as malondialdehyde (MDA) a 
product of lipid peroxidation. Other biomarkers of oxidative stress include human SOD-1 (Cu/Zn-
SOD), TNF-a, catalase and glutathione peroxidase, while C-reactive protein has been related to 
severe malaria in children
12-14
. 
 
1.2.3.1. Haemoglobin metabolism of P.falciparum 
 
 
During intra-erythrocytic development, P. falciparum ingests a large amount of hemoglobin to meet 
its nutrient requirement
15
 and to maintain osmotic stability within the host cell. Specifically, the 
malaria parasite ingests 25 to 80% of total hemoglobin content
16
. Haemoglobin molecules, taken up 
by endocytosis undergo hydrolysis in the parasite’s digestive acidic vacuole called the food vacuole. 
Cysteine and aspartic proteases are involved in hemoglobin proteolysis and have reported pH 
optimums in the range of 4.5-5.0
16
. A pH homeostasis plays an important role in the 
pathophysiology of falciparum malaria, such as host cell exploitation and responses to antimalarial 
drugs. Accordingly, baseline pH values and the mechanisms underpinning pH homeostasis in 
different parasite compartments have been of interest for several decades
17
. 
 
Endogenous production of reactive oxygen species (ROS) in parasitized erythrocytes are triggered 
following the digestion of haemoglobin and subsequent biochemical reactions in the parasites. 
Haemoglobin that is taken up by the parasites into their acid food vacuole leads to the spontaneous 
oxidation of haem iron from Fe
2+
 to Fe
3+
 (haemin) and the formation of superoxide radicals (O2 
•−
). 
The combination of O2 
•−
 and haemin inevitably leads to the generation of hydrogen peroxide (H2O2) 
and subsequently, hydroxyl radicals (
•−
OH), which are highly reactive and cytotoxic oxygen 
intermediates)
18
. Furthermore, toxic (ferroprotoporphyrin IX; containing Fe
2+
) and hemin/hematin 
(ferriprotoporphyrin IX; containing Fe
3+
) (FPIX) that are released upon haemoglobin digestion must be 
detoxified within the acid food vacuole to prevent downstream toxicity. Most of the released 
 
FPIX is biomineralized (up to 90%); to form inert hemozoin. However, there are reports that 18 
substantial amount of FPIX (even as much as 50%) escapes bio-mineralization and has to be 
degraded or sequestered by other means to prevent membrane damage and parasite death. 
 
However, some free FPIX (up to 50% according to from the food vacuole pass into the parasite 
compartment. The O2 
•−
resulting from the oxidation of haem-iron of haemoglobin are either 
detoxified by superoxide dismutase (SOD) to yield H2O2 or in a spontaneous reaction with H2O2, 
lead to the formation of 
•−
OH. In addition, ferric iron (Fe
3+
) reacts with molecular oxygen via the 
Fenton reaction pathways to generate 
•−
OH
13
 (Equation 1)
18
. 
 
 (1) 
 
 (2) 
 
 
 
 
Equation 1: The Fenton reaction 
 
These radicals are highly reactive and cause, for instance, lipid peroxidation and DNA oxidative 
damage. Additionally, H2O2 generated by the SOD activity has to be detoxified by reduction 
reaction to produce water. In P. falciparum, thioredoxin (Trx)-dependent peroxidase pathway plays 
this role because the parasites lack catalase and glutathione peroxidase
19
, which initially, raised 
doubts about the relevance of reduced glutathione (GSH) in detoxification of ROS in Plasmodium. 
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1.3. Treatment of Malaria 
 
 
World Health Organization (WHO) every year is publishing guidelines for the treatment of Malaria. 
The primary objective of treatment is to ensure complete cure that is the rapid and full elimination 
of the Plasmodium parasite from the patient’s blood, in order to prevent progression of 
uncomplicated malaria to severe disease or death, and to chronic infection that leads to malaria-
related anaemia. From a public health perspective, treatment is meant to reduce transmission of the 
infection to others, by reducing the infectious reservoir and by preventing the emergence and spread 
of resistance to antimalarial medicines
2
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Drug class of antimalarial drugs 
 
Core Principles 
 
The following are the core principles for the treatment of Malaria according to the latest update of 
 
WHO
20
 : 
 
 Early diagnosis and prompt, effective treatment of Malaria

Uncomplicated falciparum malaria can progress rapidly to severe forms of the disease, especially in 
people with no or low immunity, and severe falciparum malaria is almost always fatal without 
treatment. Therefore, programmes should ensure access to early diagnosis and prompt, effective 
treatment within 24-48 hours of the onset of Malaria symptoms. 
20 
 Rational use of antimalarial agents

To reduce the spread of drug resistance, limit unnecessary use of antimalarial drugs and better 
identify other febrile illnesses in the context of changing malaria epidemiology, antimalarial 
medicines should be administered only to patients who truly have Malaria. Adherence to a foul 
treatment course must be promoted. 

 Combination therapy

Preventing or delaying resistance is essential for the success of both national and global strategies 
for control and eventual elimination of Malaria. To help protect current and future antimalarial 
medicines all episodes of malaria should be treated with at least two effective antimalarial 
medicines with different mechanisms of action (combination therapy). 

 Appropriate weight-based dosing

To prolong their useful therapeutic life and ensure that all patients have an equal chance of being 
cure, the quality of antimalarial drugs must be ensure and antimalarial drugs must be given at 
optimal dosages. Treatment should maximize the likelihood of rapid clinical and parasitological 
cure and minimize transmission from the treated infection. To achieve this, dosage should be based 
on the patient weight and should provide effective concentrations of antimalarial drugs for a 
sufficient time to eliminate the infection in all target population. 

Treating uncomplicated P.falciparum malaria 

Treat children and adults with uncomplicated P. falciparum malaria (expect pregnant women in 
their first semester) with one of the following recommended artemisinin-based combination 
therapies (ACT): 

 Artemether + Lumefantrine

 Artesunate + Amodiaquine

 Artesunate + mefloquine

 Dihydroartemisinin + piperaquine

 Artesunate + sulfadoxine-pyrimethamine

Duration of ACT treatment 

ACT regimens should provide 3 days treatment with an artemisinin derivative. 

Revised dose recommendation for Dihydroartemisinin + piperaquine in young children 
Children < 25kg treated with Dihydroartemisinin + piperaquine should receive a minimum of 2.5 
mg/Kg body weight (bw) per day of Dihydroartemisinin and 20mg/kg bw per day of piperaquine 
daily for 3 days
20
. 
 
21 
Reducing the transmissibility of treated P.falciparum infections 
 
In low transmission areas, give a single dose of 0.25mg/kg bw primaquine with ACT to patients 
with P.falciparum malaria (expect pregnant woman, infants aged < 6 months and women 
breastfeeding infants aged < 6 months) to reduce transmission. Testing for glucose-6-phosphate 
dehydrogenase (G6PD) deficiency is not required. 
 
 
Treating uncomplicated P.Vivax, P. ovale, P. Malariae or P. knowlesi 
malaria Blood stage infection 
 
If the malaria species is not known with certainty, treat as for uncomplicated P.falciparum 
malaria. Good practice statement 
 
In areas with chloroquine-susceptible infections, treat adults and children with uncomplicated 
P.Vivax, P. ovale, P. Malariae or P. knowlesi malaria with either ACT malaria (expect pregnant 
women in their first trimester) or chloroquine. 
 
In areas with chloroquine-resistant infections, treat adults and children with uncomplicated P.Vivax, 
P. ovale, P. Malariae or P. knowlesi malaria with either ACT malaria (expect pregnant women in 
their first trimester) with ACT. Treat pregnant women in their first trimester who have chloroquine-
resistant P.Vivax malaria with quinine. 
 
1.3.1. Quinine and its synthetic derivatives 
 
 
The first class of compounds used for the successful 
treatment of malaria and drugs of choice for the present 
time were Aminoquinolines derivatives. The first 
attempt of successful treatment of malaria was made in 
the 18th century by using the bark of cinchona trees 
21
. 
Gomes et al. in 1810 extracted the cinchona bark, but 
only after a decade an active ingredient of quinine 
(Fig.4) was isolated and made Malaria the first disease 
 
for which a pure compound was used for the treatment. The structure elucidation and different 
synthetic routes have come up in near 19th century
22
. 
 
In 1856, chemist William Henry Perkins, set out to synthesize quinine. His efforts resulted in the 
first synthetic textile dye called “mauve” and not in quinine. Paul Ehrlich noticed that methylene 
blue was particularly effective in staining malaria parasites (Fig.5). He rationalized that this dye 
 
22 
 
Figure 4. Active ingredients of quinines, Quinine 
1 and Quinidine 2 
might also be selectively toxic to the parasite. In 1891, Ehrlich and Guttmann cured two malaria 
patients with methylene blue, which became the first synthetic drug ever used in therapy. Thus, 
methylene blue constituted the basis for the development of synthetic antimalarials, even it has not 
been used further at that time. 
 
Mode of action of aminoquinoline classes of 
compounds is still a matter of debate despite the 
overwhelming importance. Various theories have 
been proposed and reviewed and they all agree that 
 
Figure 5.
 
Chemical structure of Methylene Blue
 CQ interacts with the parasite’s ability to digest 
haemoglobin. During its erythrocytic stages, the parasite consumes large quantities of haemoglobin 
from its host cell, either for the purpose of amino acid supply, or simply to create space inside the 
erythrocyte. Haemoglobin is shuttled by vesicles to a specialized organelle called digestive vacuole 
(DV). Early biochemical studies demonstrated that CQ was able to inhibit DNA and RNA 
synthesis. However, the interaction of CQ with DNA does not explain the antimalarial activity and 
the selective toxicity of this compound. 
 
The mechanism of action of CQ is active only against the erythrocytic stages of malaria parasites. 
During the feeding process of the parasites, CQ was able to inhibit the haemoglobin degradation. 
The 4-aminoquinoline derived drugs have been proposed that selectively target the haemoglobin 
degradation which is specific to parasites
23
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Chemical structure of Aminoquinolines 23 
 Aminoquinoline derived drugs (Fig.6) are known to inhibit the hematin formation by complexing 
with ferriprotoporphorin IX (FPIX) thereby prevents its polymerization into hemozoin, which 
results in parasite death. Most NMR and molecular modeling studies
23
 show a face-to-face π 
staggering of the porphyrin and quinoline systems, although a structure showing an edge-to-face 
complex with the ring nitrogen atom sitting above the ring iron center has also been reported. Very 
recently, structure determination by NMR spectroscopy showed CQ sitting in a central position over 
the outermost porphyrin rings of a FPIX–CQ 4:2 complex. Most researchers assume that the 
buildup of noncrystalline FPIX, either in its free form or as a FPIX–CQ complex, finally kills the 
parasite. Considerable evidence has accumulated in recent years that antimalarial drugs such as CQ 
act by forming complexes with FP, the hydroxo or aqua complex of Ferriprotoporphyrin IX (Fe(III) 
FP), derived from parasite proteolysis of host haemoglobin. Remarkable data supports the 
hypothesis that hematin is the target of 4-aminoquinoline class of compounds. 4-AQ are weak bases 
and are expected to accumulate in an acidic food vacuole to many folds
23
. 
 
 
 
 
1.3.2. Artemisinin and its synthetic derivatives 
 
 
During the latter part of the Vietnam War, in the late 1960s 
to early 1970s, malarial infections, combined with drug 
resistance to common anti-malarial drugs, resulted in huge 
losses of military personnel on both combating sides. 
Responding to a request by the North Vietnamese, the 
Chinese government engaged in a national effort involving 
more than 50 institutes to develop improved anti-malarial 
drugs
24
. 
 
Figure 7. Artemisia annua 
 
The most important discovery of these efforts is Artemisinin (ART). Artemisinin also called 
qinghaosu, is derived from the sweet wormwood plant, Artemisia annua (Fig.7). Sweet wormwood 
has been used by the Chinese as a herbal medicine for centuries and the drug was brought into 
modern medicine by Tu Youyou, who was awarded the Nobel prize for Medicine in 2015. 
Artemisinin is a sesquiterpene lactone with an endoperoxide bridge (essential for its action). After 
 
the initial discovery of ART, medicinal chemists made great strides in improving the efficacy of 24 
ART. A set of ART derivatives including dihydroartemisinin (DHA), artemether, artesunate and 
arteether, all modified at the C10 position, were produced (Fig.8). These ART derivatives, together 
with the ART prototype, are collectively called artemisinins (ARTs). 
 
Second generation derivatives, which structurally deviate much more from the ARTs but all contain 
the crucial endoperoxide bridge, were later developed. Although original applications of ARTs 
were reported in anti-malarial treatment, activities against cancer, viruses and other parasites such 
as schistosoma, clonorchis, Toxoplasma and Leishmania have now also been documented. 
Therefore, it appears ARTs possess inhibitory activities against an array of different maladies
24
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. : Artemisinin (ART) and some of its derivatives. The endoperoxide bond constitutes the pharmacophore 
for the action of ARTs. Direct ART derivatives are usually modifiers of ART at the C10 position. Some other 
endoperoxides differ greatly structurally but also manifest potent anti-malarial activities. 
 
1 Artemisinin. 2a Dihydroartemisinin (DHA). 2b Artemether. 2c Arteether. 2d Artesunate. 3, 4 An analogue with close 
structure to artemisinin. 5a, 5b Enantiomers with similar activities against malaria parasites. 6 An antimalarial 
tetraoxane. 7 OZ439 (in clinical trial). 
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1.3.2.1. Mechanism of action of artemisinin, different Hypothesis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Graphical representation of the hypothetical mechanism of action of Artemisinin 
 
Understanding the mode of action of Artemisinin is important for designing artemisinin derivatives 
with better antiparasitic activity and predicting mechanisms of resistance. Despite tremendous 
research efforts on artemisinin since its discovery, there is still considerable debate about the mode 
of action on malaria parasites. Over the years a lot of researchers tried to understand the mode of 
action of Artemisinin and four are the main hypothesis
25-27
. 
 
 The C-radical Hypothesis

 The Heme Hypothesis

 The SERCA Hypothesis

 The Co-factor Hypothesis
 
 
Main Hypothesis 
 
Artemisinins are considered prodrugs that are activated to generate carbon-centered free radicals or 
reactive oxygen species (ROS). As the O-centered radical formed upon cleavage is unable to 
oxidatively cycle, ROS is less likely important for the action of artemisinins. Because Fe
2+
 is a 
catalyst that can generate free radicals from peroxides and large amounts of iron accumulate in the 
food vacuole, hemoglobin, heme, and free iron has been studied as key molecules participating in 
the initial artemisinin interaction and cleavage event
26
. 
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‘The C-radical Hypothesis’ 
 
Fe2+ induces reductive cleavage of the peroxide, referred to generally as the ‘Fenton reaction’ to 
form O-radicals that in turn interact with hydrocarbon scaffold encapsulating the peroxide to 
generate C-radicals. Those radicals are held to be the toxic agents for parasites. In any case, the 
nature of the target, and whether indeed an intracellular alkylation takes place, remain undefined. 
By definition, as spin unpairing in the generation of the radical has taken place, a penultimate step 
in the hypothetical scheme requires an electron transfer, presumably from whatever the radical 
product is, back to the initiating metal such that a caution is produced. The caution may be 
quenched by a nucleophile such as water or endogenous thiol. Alternatively, an endogenous redox-
active substrate, such as the reduced conjugate of a flavin, may donate an electron to generate an 
incipient carbanion that may me protonated. Alternatively, dioxygen in principle may form a peroxy 
radical that may undergo further SET to generate a hydroperoxide. In any event, such downstream 
events have not been considered within the framework of this hypothesis
27
. 
 
‘The Heme Hypothesis’ 
 
Heme has been intensively studied as an 'activator' of artemisinins and other antimalarial peroxides, 
and indeed the hypothesis seemingly has become firmly embedded in the underlying brickwork of 
the scientific edifice. The locus of activity of the peroxides interacting with the heme is considered 
to be the parasite digestive vacuole. The basis for the nanomolar activities of artemisinins and 
synthetic peroxides is variously ascribed to heme-Fe
2+
-mediated generation of C-radicals from the 
peroxides, formation of heme-artemisinin adducts that are held either to engage in redox cycling 
with concomitant generation of ROS or to inhibit the formation of hemozoin. In the last case, just 
like the aminoquinolines and arylmethanols, the peroxides are not the active agents, but exert their 
parasitical effects through allowing the build-up of free heme-Fe
3+
, the ultimate cytotoxic entity
27
. 
Wang and his group published in nature communication (2015) that artemisinin activation is mainly 
heme dependent, which they believe resolve previous arguments regarding the source of iron 
required for the drug activation. Artemisinin activation at the early ring stage seems to rely on 
parasite’s heme biosynthesis, whereas drug activation depends on hemoglobin digestion as the main 
heme source at the latter parasite stages, which determines the high specificity of the drug towards 
the parasite
13
. 
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‘The SERCA Hypothesis’ 
 
Modulation by artemisinin and synthetic peroxides of operation of the Plasmodium falciparum 
sarco-endoplasmic reticulum calcium pump SERCA Ca
2+
-ATPase ATP6 is held to occur by 
binding of the artemisinin or synthetic peroxide into a cleft on the cytosolic side of transporter. 
However, it is important to recognize that Fe
2+
 is regarded as essential pre-requisite for this 
mechanism that is, the bound peroxide is ‘’fixed’’ covalently by an SET reaction with Fe2+27. 
 
‘The Co-factor Hypothesis’ 
 
Artemisinin and its synthetic peroxides rapidly oxidize reduced conjugates of flavin cofactors, or 
those of flavin cofactor precursors such as riboflavin, and other similarly susceptible endogenous 
substrates that play a crucial role in maintaining intraparasitic redox homeostasis. Given that the 
means by which the parasite is able to control the generation of cytotoxic reactive oxygen species 
(ROS) is suppressed, the consequence will be rapid build-up of ROS. Overall, redox homeostasis is 
overwhelmed. This proposal differs fundamentally to the other three in that the peroxide overall 
acts as a two-electron oxidant, in common with a vast family of related reactions involving 
 
peroxides. So in this sense, artemisinins and synthetic peroxides are considered to act as 
oxidant drugs. Iron does not react with the peroxide, but its presence markedly, not least because 
its redox cycling contributes to generation of ROS, and effects the hezose monophosphate shunt 
involved in the generation of NADPH
27
. 
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1.3.3. Artemisinin based combination therapies (ACTs) 
 
Artemisinin-based combination 
therapy (Table 2) is a combination 
of a rapidly acting artemisinin 
derivative with a longer-acting 
partner drug. The artemisinin 
component rapidly clears parasites 
from the blood (reducing parasite 
numbers by a factor of 
approximately 10 000 in each 48-h 
 
Table 2. Treatment of uncomplicated P.falciparum malaria 
asexual  cycle)  and  is  also  active 
 
against the sexual stages of parasites that mediate onward transmission to mosquitos. 
 
The longer-acting partner drug clears the remaining parasites and provides protection against 
development of resistance to the artemisinin derivative. Partner drugs with longer elimination half-
lives also provide a period of post-treatment prophylaxis.
2,28
. The basic ACTs are presented below 
and are the following: Artemether + Lumefantrine, artesunate + Amodiaquine, artesunate + 
mefloquine, Dihydroartemisinin + piperaquine and artesunate + sulfadoxine-pyrimethamine
20
. 
Dosing of ACTs 
 
ACTs regimens must ensure optimal dosing to prolong their useful therapeutic life in order to 
maximize the likelihood of rapid clinical and parasitological cure, minimize transmission and retard 
drug resistance. It is essential to achieve effective antimalarial drug concentration for a sufficient 
time (exposure) in all target populations in order to ensure high cure rates. The dosage 
recommendations below are derived from understanding the relationship between dosage and the 
profiles of exposure to the drug (pharmacokinetics) and resulting therapeutic efficacy 
(pharmacodynamics) and safety. Some patient groups, notably younger children, are not dosed 
optimally with the ‘’dosage regimens’’ recommended by manufacturers, which compromises 
efficacy and fuels resistance. In these guidelines when there was pharmacological evidence that 
certain patient groups are not receiving optimal doses, dose regimens were adjusted to ensure 
similar exposure across all patient groups. 
 
 
 
29 
Weight-based dosage recommendations are summarized below. While age-based dosing may be 
more practical in children, the relation between age and weight differs in different populations. 
Age-based dosing can therefore result in under-dosing of some patients, unless large, region-
specific weight-for-age databases are available to guide dosing in that region
20
. 
Artemether + Lumefantrine 
 
Comments: An advantage of this ACT is that Lumefantrine is not available as monotherapy and has 
never been used alone for the treatment of malaria. 
 
Absorption of Lumefantrine is enhanced by co-administration with fat. Patients or caregivers 
should be informed that this ACT should be taken immediately after food or fat containing drink, 
particularly on the second and third days of treatment
20
. 
Artesunate + Amodiaquine 
 
Comments: No Significant changes in the pharmacokinetics of Amodiaquine or its metabolite 
desethylamodiaquine have been observed during the second and third trimesters of pregnancy; 
therefore, no dosage adjustments are recommended. 
 
No effect of age has been observed on the plasma concentration of Amodiaquine, so no dose 
adjustment by age is indicated. Few data are available on the pharmacokinetics of Amodiaquine in 
the first year of life
20
. 
Artesunate + mefloquine 
 
Comments: Mefloquine was associated with increased incidences of nausea, vomiting, dizziness, 
dysphopria and sleep disturbance in clinical trials, but these symptoms are seldom debilitating, and, 
where this ACT has been used, it has generally been well tolerated. To reduce acute vomiting and 
optimize absorption, the total mefloquine dose should preferably be split over 3 days, as in current 
fixed-dose combinations. 
 
Artesunate + sulfadoxine-pyrimethamine 
 
Comments: The disadvantage of this ACT is that is not available as a fixed-dose combination. This 
may compromise adherence and increase the risk of contribution of loose artesunate tablets, despite 
the WHO ban on artesunate monotherapy. Resistance is likely to increase with continued 
widespread use of Sulfalene-pyrimethamine and cotrimoxazole. Fortunately, molecular markers of 
resistance to antifols and sulfonamides correlate well with therapeutic responses. These should be 
monitored in areas in which this drug is used
20
. 
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Dihydroartemisinin + piperaquine 
 
Comments: Piperaquine (PQ) prolongs the QT interval by approximately the same amount as 
chloroquine but by less than quinine. It is not necessary to perform an electrocardiogram before 
prescribing Dihydroartemisinin + piperaquine, but this ACT should not be used in patients with 
congenital QT prolongation or who have a clinical condition or are on medication that prolong the 
QT interval. 
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 Proportion of antimalarial treatments from 2010- 2015  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. The proportion of ACTs antimalarial treatments from 2010 
to 2015 
 
 
 
 
 
 
Regarding the latest report (2016) of 
 
WHO
2
, based on nationally 
representative household surveys, the 
proportion of antimalarial treatments 
that are ACTs (for children with both 
a fever in the previous 2 weeks and a 
positive RDT at the time of survey) 
increased from a median of 29% in 
2010–2012 (IQR: 17–55%) to 80% in 
2013–2015 (IQR: 29–95%) (Fig.10). 
However, the ranges associated with 
 
the medians are wide, indicating large variation between countries, and the number of household 
surveys covering anyone 3-year period is comparatively small. Antimalarial treatments are more 
likely to be ACTs if children seek treatment at public health facilities or via community health 
workers than if they seek treatment in the private sector
20
. 
 
1.3.3.1. ACTs not currently recommended for general use 
 
 
According to the latest guideline for the treatment of malaria of WHO for Malaria, the pipeline for 
new antimalarial drugs is healthier than ever before, and several new compounds are in various 
stages of development. Some of them are still in the pre-registration phase and are not discussed in 
the Malaria report. The following are some novel antimalarial combinations registered in some 
countries. 
 
 Artesunate + Pyronaridine

 Arterolane + piperaquine

 Artemisinin + naphtoquine
 
 
A systematic review of artesunate + Pyronaridine included six trials with a total of 3718 patients. 
The mentioned combination showed good efficacy as compared with Artemether + Lumefantrine 
and artesunate + mefloquine in adults and older children with P.falciparum malaria, but the current 
32 
evidence for young children is insufficient to be confident that the drug is as effective as currently 
recommended options. Further studies to characterize the risk for hepatotoxicity I needed. 
Preliminary data from repeat-dosing studies are reassuring. 
 
Arterolane + piperaquine is a combination of a synthetic ozonide and piperaquine phosphate that 
is registered in India for use only in adults. There are general insufficient data to make 
recommendations. 
 
Artemisinin + naphtoquine is also a combination of two relatively old compounds that are 
currently being promoted as a single dose regimen, contrary to WHO advise for 3 days of the 
artemisinin derivative. There are currently insufficient data from rigorously conducted randomized 
controlled trials to make general recommendations
20
. 
 
1.3.4. Antimalarial drug resistance 
 
 
The exact definition of an antimalarial drug resistance is the ability of parasite strain to survive 
and/or multiply despite administration and absorption of an antimalarial drug given in doses equal 
to or higher than those usually recommended, provided the drug exposure is adequate. Resistance to 
antimalarial drugs arises because selection of parasites with genetic changes (mutations or gene 
amplifications) that confer reduced susceptibility. 
 
Unfortunately, resistance has been documented to all classes of antimalarial medicines, including 
the artemisinin derivatives, which is the major threat to malaria control. Widespread inappropriate 
use of antimalarial drugs exerts a strong selective pressure on malaria parasites to develop high 
levels of resistance. It can be prevented or its onset slowed considerably by combining antimalarial 
drugs with different mechanisms of action and ensuring high cure rates through full adherence to 
correct dose regimens. If different drugs with different mechanisms of resistance are used together, 
the emergence and spread of resistance should be slowed
28,29
. 
Clinical and parasitological assessment of therapeutic efficacy should include: 
 
 Confirmation of the quality of the antimalarial medicines tested;

 Molecular genotyping to distinguish between re-infections and recrudescence and to identify 
genetic markers of drug resistance;

 Studies of parasite susceptibility to antimalarial drugs in culture; and

 Measurement of antimalarial drug levels to assess exposure in cases of slow therapeutic 
response or treatment failure
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 Recurrent Falciparum Malaria 
 
Recurrence of P. falciparum malaria can result from re-infection or recrudescence (treatment 
failure). Treatment failure may result from drug resistance or inadequate exposure to the drug due 
to sub-optimal dosing, poor adherence, vomiting, unusual pharmacokinetics in an individual or 
substandard medicines. It is important to determine the patient’s history whether he or she vomited 
the previous treatment or did not complete a full of treatment. 
 
When possible, treatment failure must be confirmed parasitologically. This may require referring 
the patient to a facility with microscopy or LDH-based RTDs, as P. falciparum histidine-rich 
protein-2 (PfHRP2)-based tests may remain positive for weeks after the initial infection, even 
without recrudescence. Referral may be necessary anyway to obtain second line-treatment. In 
individual patients, it may not be possible
29
. 
 
1.3.4.1. Definition of artemisinin resistance 
 
Clinical artemisinin resistance is defined as delayed parasite clearance; it represents a 
partial/relative resistance that has thus far only affected ring-stage parasites. Delayed parasite 
clearance following treatment with an ACT is of paramount concern to WHO. Nevertheless, the 
majority of patients who have delayed parasite clearance following treatment with an ACT are still 
able to clear their infections, as long as the partner drug remains effective. The identification of the 
PfKelch13 (K13) mutations has allowed for a more refined definition of artemisinin resistance that 
includes information on the genotype. However, we have yet to fully understand which specific 
mutations within the K13 domain are most associated with artemisinin resistance. The current 
definition of artemisinin resistance is subject to change based on new evidence. There is no 
evidence that higher levels of artemisinin resistance (full resistance) have emerged
30
. 
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1.3.5. Antimalarial drugs and Oxidative stress 
 
The pharmacological therapy currently used is based on the susceptibility of the genus Plasmodium 
to free radicals and oxidants, as well as the interference or inhibition of a metabolic synthesis 
pathway of a molecule essential to the parasite. The ROS and iron byproducts present in the pRBCs, 
which are rare in healthy RBCs, remain the typical pRBC targets. Aminoquinolines such as 
chloroquine (CQ) and ARTs are thought to target these redox-active heme byproducts generating an 
oxidative stress fatal to the parasite. Considering that pRBC are selectively damaged by oxidants, 
the interest for new oxidant drugs with antimalarial properties began more than 30 years ago
31,32
. 
 
 
At this point, it is important to clarify that there are two types of oxidants, some are intrinsically 
oxidizing (e.g., quinones and quinoid compounds, peroxides), while others do not have apparent 
redox properties but indirectly induce oxidation reactions by their mechanisms of action (e.g., 
aminoquinolines). In this view, artemisinin-like endoperoxides are oxidant while the oxidative 
stress generated by chloroquine is more a downstream event arising from its strong interaction with 
heme. This effect may be due to the drug’s ability to promote the direct production of free radicals 
or by inhibiting molecules with antioxidant activity. 
 
 
 
 
1.4. RBC membrane modifications in pro-oxidant mutations 
 
 
 
A number of hemolytic disorders are known to damage the RBC membrane increasing the 
production of free radicals originating from denatured hemoglobin species (hemichromes), 
invariably present in thalassemia, sickle cell disease or with a decreased ability of RBCs to deal 
with extracellular oxidants as in G6PD deficiency. It is noteworthy that approximately 7% of world 
population is affected by those mutations which have been selected by malaria and protect patients 
from its severe manifestations. The tyrosine phosphorylation of band 3 is increased in 
hemoglobinopathies even in the absence of high reticulocyte count
33-37
. 
 
At least two mechanisms might be involved in the increased tyrosine phosphorylation of band 3 in 
these hemoglobin disorders, probably related to the endogenous reactive oxygen intermediates 
generated by the abnormal erythrocyte: an inhibition of protein tyrosine phosphatase activity or an 
35 
activation of the protein tyrosine kinase p72syk. The mechanisms leading to its phosphorylation and 
its pathophysiological significance have been partially defined. Recently Ferru and her colleagues 
described that band 3 phosphorylation appears to be increased in intermediate thalassemia and that 
this phenomenon is closely related to the formation of hemichromes. Band 3 phosphorylation and 
hemichromes formation have been also described in malaria-infected RBC
38
. In both pathological 
situations, band 3 phosphorylation appears to play a permissive role in the release of membrane 
microparticles
37
. 
 
Current knowledge appears to be still insufficient to explain the molecular details of the underlying 
mechanism, although some recent findings clearly indicate a role of band 3 phosphorylation in the 
regulation of metabolism mediated by the binding of deoxygenated hemoglobin (Hb) and in the 
modification of the affinity between band 3 and ankyrin following oxidative stress. In most 
instances, those mutations do not seem to directly affect the parasite growth but seem to unbalance 
the complex relationships that undergo between the erythrocytes and their intracellular parasites. 
 
 
 
 
1.4.1. Band 3 tyrosine phosphorylation 
 
 
 
Band 3 is the most abundant RBC membrane protein and represents one of the major components of 
the junctional complexes that connect the lipid bilayer to the cytoskeleton. It has been previously 
found that the oxidation of two cysteine residues in the band 3 cytoplasmic domain leads to the 
docking of Syk kinase. RBC appears to possess a mechanism able to recruit Syk kinase to a fraction 
of less glycosylated band 3 molecules capable of forming disulfide dimers. It has been previously 
demonstrated that HMC bind to band 3 causing free iron accumulation and free radical production. 
 
RBCs also respond by activating tyrosine kinases determining the tyrosine (Tyr) phosphorylation of 
band 3, the major linkage between the cytoskeleton and the lipid bilayer. In RBCs, 
hyperphosphorylation of band 3 has been constantly reported in all the prooxidant hemolytic 
disorders and in malaria
39-42
. 
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1.4.2. Hemichromes (HMC)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Confocal image of pRBC 
with hemicromes bounded to the red 
cell membrane 
 
 
 
 
 
 
 
 
The autoxidation of Hb (Fe
II
) occurs spontaneously in normal 
RBCs. MetHb can also be produced by oxidants and ROS. In 
normal conditions the reaction is reversible and production of 
metHb is in balance with the conversion of metHb back to Hb. For 
this reason, Hemichrome is rarely found in erythrocytes in situ, 
even though the reaction dynamics of Hb with molecular oxygen 
(O2) make it a particularly suitable O2 carrier. Hb can bind O2 in 
ferrous form to carry out its physiological functions
43
. 
 
 
 
 
During this reversible O2 binding, the oxygenated form of Hb (HbO2) is known to be oxidized by 
the bound oxygen to the ferric met form (metHb), which cannot be oxygenated, and is thus 
physiologically inactive. Although metHb is reduced back to the ferrous state by an 
intraerythrocytic nicotinamide adenine dinucleotide (NADH)-dependent reducing system, it has 
been suggested that its oxidation (autoxidation) process can be followed by transformation of the 
oxidized molecule (high-spin Fe
3+
) into a species absorbing as a low-spin compound, i.e., 
hemichrome, the formation of which can result in the accumulation of soluble and insoluble 
hemichromes and precipitation. 
 
Despite these findings, direct evidence of hemichrome formation in normal erythrocytes is lacking. 
On the contrary, in pathological conditions, increased oxidative stress and/or impaired antioxidant 
defence enhance the production of metHb, the generation of ROS in consequently the regeneration 
of unstable Hb and irreversible Hb oxidation products, giving hemichrome forms
44
. 
 
The first area in which hemichrome formation plays a role, although perhaps a negative role, is in 
the formation of Heinz bodies and the subsequent destruction of red cells. 
 
It has been shown that HMC bind to the cytoplasmic portion of band 3 of the erythrocyte 
membrane. The binding of hemoglobin to band 3 of the erythrocyte membrane involves insertion of 
the N-terminal peptide of band 3 into the central cavity of hemoglobin between the β chains 45. 
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This binding is enhanced for deoxyhemoglobin, in which the distance between the β chains is 
greater, and is blocked by cross-linking the β chains. The binding of HMC to band 3 also involves 
the same N-terminal cytoplasmic peptide. However, the binding is much stronger than for 
hemoglobin and it does not involve insertion into the central cavity. Instead, it involves the 
interaction of two hemoglobin molecules with each band 3 chain
46
. 
 
HMC rapidly copolymerize with the soluble cytoplasmic domain of the erythrocyte membrane band 
3 and form an insoluble copolymer. It has been suggested that in the intact cell the same binding of 
HMC to band 3 causes a clustering of band 3 and results in the formation of insoluble Heinz bodies. 
This hypothesis is supported by several studies of abnormal haemoglobins that show that the 
formation of Heinz bodies correlates with the presence of HMC bound to the membrane. The cells 
with Heinz bodies are rapidly taken out of circulation. Thus in splenectomized patients increased 
levels of Heinz bodies are detected. It is clear, at least with certain abnormal haemoglobins, that the 
hemichrome formation and subsequent Heinz body formation are part of the etiology of hemolytic 
anemia. Finally, in pRBCs HMC release their heme into the erythrocyte membrane with consequent 
lipid peroxidation, biomolecule oxidation and membrane destabilization. A chain of events is 
induced by the generation of HMC during the intra-erythrocyte parasite development
44
. 
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1.5. Syk inhibitors as treatment for Malaria  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The role of band 3 in the life of the malarial parasite with (w/) and without (w/o) Syk tyrosine kinase 
inhibition. Hb, hemoglobin; p, phosphorylation of band 3; RBC, red blood cell. Professional illustration by 
Somersault18:24.
1 
 
 
 
 
AE1 or Band 3 is the most abundant erythrocyte membrane protein which constitutes the major 
attachment site of the spectrin-based cytoskeleton to the erythrocyte’s lipid bilayer and thereby 
contributes  critically  to  the  stability  of  the  red  cell  membrane
47
.  Recently,  Pantaleo  et  all 39 
demonstrated that during the intra-erythrocytic stage of Plasmodium falciparum’s life cycle, band 3 
becomes tyrosine phosphorylated in response to oxidative stress, leading to a decrease in its affinity 
for the spectrin/actin cytoskeleton and causing global membrane destabilization (Fig.12). According 
to this hypothesis, this membrane weakening facilitates to parasite egress and the consequent 
dissemination of released merozoites throughout the bloodstream. 
 
Syk kinase inhibitors both prevent parasite-induced band 3 tyrosine phosphorylation and inhibit 
parasite-promoted membrane destabilization. Indeed, the same Syk kinase inhibitors suppress 
merozoite egress near the end of the parasite’s intra-erythrocytic life cycle. Because the entrapped 
merozoites die when prevented from escaping their host erythrocytes and since some Syk inhibitors 
have displayed long term safety in human clinical trials, they are a promising class of anti-malarial 
drugs that can suppress parasitemia by inhibiting a host target that cannot be mutated by the parasite 
to evolve drug resistance. Syk inhibitors like R406 are in various stages of development and trials 
are currently underway investigating Syk inhibition in a wide range of disorders from chronic 
immune disorders such as immune thrombocytopenic purpura to malignancies such as 
retinoblastoma. Given their general safety in these initial trials, a case can be made for a clinical 
translational trial of a Syk TKI in malaria
48-51
. 
 
 
 
1.5.1. Syk inhibitors and their molecular synthesis 
 
 
 
Syk inhibitors act as ATP-competitive inhibitors of Syk. These compounds have already used in 
several inflammatory and allergic diseases. Specifically, R406 (Fig.13A), showed its long-term 
safety in large studies to cure rheumatoid arthritis, and is currently in clinical trial (phase 2); 
furthermore the pyrimidine carboxamide derivatives, as Syk inhibitor II (Syk II) and IV (Syk IV) 
(Fig.13E and 13D) are used to treat allergic diseases. While Imatinib (Fig.13F), marked as 
Gleevec by Novartis, acts as tyrosine kinase inhibitor and is a well-tolerated drug for long-term 
treatment of several cancerous diseases, most notably Philadelphia chromosome-positive (Ph+) 
chronic myelogenous leukemia
48
 (CML). 
 
Piceatannol (Fig.13B) (3, 4’, 3’, 5-trans-trihydroxystilbene) is a resveratrol analogue with 
antioxidant, anticancer and anti-inflammatory activities. Entospletinib (Fig.13C) (GS-9973) is an 
oral, selective inhibitor of spleen tyrosine kinase. This multicenter, phase 2 study enrolled subjects 
with relapsed or refractory chronic lymphocytic leukemia (CLL; n = 41) or non-Hodgkin lymphoma 
 
40 
(n = 145). P505-15 (Fig.13G) (also known as PRT062607) is a novel, highly selective, and orally 
bioavailable small molecule SYK inhibitor (SYK IC50 = 1 nM) with anti-SYK activity that is at least 
80-fold greater than its affinity for other kinases. There are findings supporting the ongoing 
development of P505-15 as a therapeutic agent for B-cell malignancies. 
 
Figure 13. Molecular synthesis of different Syk inhibitors such as R406, Piceatannol, Entospletinib, SYK IV, SYK II, 
Imatinib and P505-15. 
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1.6. Drug combinations 
 
Drug combination is most widely used in treating the most dreadful diseases, such as cancer, AIDS 
and Malaria. The main aims are to achieve synergistic therapeutic effect, dose and toxicity 
reduction, and to minimize or delay the induction of drug resistance. Toxicity reduction and 
resistance minimization benefits could also be the outcomes of synergism. The main obstacles to 
the success of combination treatment in preventing the emergence of resistance will be inadequate 
treatment (e.g., substandard drugs, incorrect dosing, unusual pharmacokinetics, poor adherence) and 
use one of the combination partners alone. This is why blister packing has been encouraged and 
fixed-dose combinations are now being developed and recommended
52
. 
 
1.6.1. Terms of Synergy, additivity and antagonism 
 
When the addition of one agent apparently increases the effect of the other, so that the effect of a 
combination appears to be greater than would be expected; the term “synergism” is used to describe 
these situations. The term “antagonism” is used when the effect of the combination is less effective 
than the sum of the individual effects; without synergism and antagonism, the two individual effects 
are “additive”53. 
 
 
1.6.2. Combination index by Chou-Talalay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Combination index values and its description 
 
 
 
 
In 1984 Chou and Talalay jointly introduced 
a concept called the “Combination Index” 
(CI) to quantitatively depict synergism (CI). 
Users of the index (CI) claim that the Chou-
Talalay Combination Index is based on the 
median-effect principle which is derived 
from the “mass action law” principle. Chou 
declared that “synergism is basically a 
physiochemical mass-action issue, not a 
statistical issue; determine synergism with 
CI values, not with p-values” 
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 52,54. 
 
 
 
Calculation of the combination index: Chou and Talalay defined a “combination index” CI as 
 
follows: Using a combined dose, d1 of agent A mixed with d2 of agent B so as to achieve 50% 
 
response, then calculating:  
 
 
After the IC50 concentration of the combination is obtained, the needed amount of each drug and the 
 
CI is calculated as follows: 
 
 
 
 
IC50 of combination +   Concentration of Drug B 
IC50 of Drug A  IC50 of Drug B  
 
 
 
 
The CI is the natural law–based general expression of pharmacologic drug interactions. It is shown 
to be the simplest possible way for quantifying synergism or antagonism. Its simplicity in 
equations, experimental designs, and data analysis features efficiency, economy, and reducing the 
experimental size of animals used or the number of patients needed for drug combination clinical 
trials. The general theory of the MEP of the mass-action law, its CI algorithm, and its computerized 
simulation have paved the way for future drug combination studies, as indicated by the broad 
acceptance in scientific applications and by the rapid increase in citation numbers. 
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1.6.3. Isobologram analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Isobologram representation 
 
 
 
 
 
The isobologram analysis (Fig.14) 
provides a graphical presentation of the 
nature of interaction of two drugs, i.e., drug 
A and drug B. First, in a two-coordinate 
plot with one coordinate representing 
concentration of drug A and the other 
representing concentration of drug B, the 
concentrations of drugs A and B required 
to produce a defined effect x (e.g., IC50, A 
and IC50, B when x=50%), when used as 
single agents, are placed on the x and y-
axes, respectively. The line of 
 
additivity is constructed by connecting these two points (e.g., (IC50, A, 0) and (0, IC50, B) for a 50% 
effect isobologram plot). Second, the concentrations of the two drugs used in combination to 
provide the same effect x (e.g., x=50%), denoted by point (CA, x, CB, x), are placed in the same 
plot. Synergy, additivity, or antagonism is indicated when this point is located below, on, or above 
the line, respectively. 
 
Τhe method is relatively simple and is not limited by whether the dose-effect relationships are 
hyperbolic or sigmoidal, whether the effects of the drugs are mutually exclusive or nonexclusive, 
whether the ligand interactions are competitive, noncompetitive or uncompetitive, whether the 
drugs are agonists or antagonists, or the number of drugs involved. The equations for the two most 
widely used methods for analyzing synergism, antagonism and summation of effects of multiple 
drugs. It can be shown that the isobologram is valid only for drugs whose effects are mutually 
exclusive, whereas the fractional product method is valid only for mutually non-exclusive drugs 
which have hyperbolic dose-effect curves. 
 
Furthermore, in the isobol method, it is laborious to find proper combinations of drugs that would 
produce an isoeffective curve, and the fractional product method tends to give indication of 
synergism, since it underestimates the summation of the effect of mutually nonexclusive drugs that 
have sigmoidal dose-effect curves. The simplified experimental design proposed for multiple drug-
effect analysis has the following advantages: It provides a simple diagnostic plot (i.e., the median- 
44 
effect plot) for evaluating the applicability of the data, and provides parameters that can be directly 
used to obtain a general equation for the dose-effect relation; the analysis which involves 
logarithmic conversion and linear regression can be readily carried out with a simple programmable 
electronic calculator and does not require special graph paper or tables; and the simplicity of the 
equation allows flexibility of application and the use of a minimum number of data points. This 
method has been used to analyze experimental data obtained from enzymatic, cellular and animal 
systems
54
. 
 
1.6.3.1. Isobologram analysis in triple combinations 
 
However, such a generalization to the analysis of more than two drugs does not allow investigation 
of the contribution of each drug to the whole combination effect. A combination of three drugs (A, 
B, and C) with a synergistic effect (CI < 1) could result from the synergistic effect between A and B 
only. A complete understanding of the contribution of each drug to the whole combination effect 
would require an assessment over all the subcombinations which is generally not feasible in 
practice. When the combination is based on logic such as the combination of two new 
investigational drugs (A and B) with a reference treatment (C), the analysis should follow the same 
logic in order to show here that A and B are synergistic, and that the combination of A + B 
(considered as a new single agent) with the reference treatment C is also synergistic
55
. 
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2. AIM OF THE PROJECT 
 
 
Recently it has been demonstrated that Syk inhibitors represent a new class of antimalarial drugs by 
suppressing merozoite egress by inhibiting the host target that cannot be mutated by the parasite to 
evolve drug resistance. It is worth noting that WHO recommends artemisinin-based combination 
therapies (ACTs) for the treatment of uncomplicated malaria caused from the P. falciparum 
parasite, by combining two active drugs with different mechanisms of action. Unfortunately, ACTs 
are losing their efficacy in large areas of South East Asia with the appearance of increasing 
resistance. The resistance to ACTs is a major thread for the control and elimination of malaria due 
to P. falciparum. To reduce the risk of recrudescence and emergence of resistant microbes, a new 
drug treatment for malaria should determine a more rapid and complete elimination of parasites 
from the blood, along with rapid amelioration of symptoms. Notably, these requisites are also 
essential to prevent and treat severe malaria. The main goal of this study is to establish new 
effective antimalarial combinations that possess the following pre-requisites: 
 
 To potentiate synergically the artemisinins

 To exert a synergic effect also in combination with the most widely used ACT

 To be effective in all stages of the asexual parasite growth

 To be effective on all sexual and asexual development stages of P. falciparum

 To have a long plasma half-life
 
 
Taking into consideration both the urgent need of new antimalarial combinations and Syk inhibitors 
as potential antimalarial drugs, this work has two main goals: 
 
1. To test the in vitro combination activity of Syk inhibitors with currently used 
antimalarial drugs such as ART’s and quinolines in order to determine their possible 
synergy. 
 
2. To understand how Syk inhibitors potentiate the artemisinin activation, whereby 
ARTs are considered prodrugs that are activated to generate ROS which can destroy 
the parasite intraerythrocytically. 
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3. MATERIAL AND METHODS 
 
 
3.1. Cultivation of P. falciparum-infected RBCs. 
 
 
Freshly drawn blood (Rh+) from healthy adults of both sexes was used. Patients provided written, 
informed consent before entering the study. The study was conducted in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki. Blood anti-coagulated with heparin 
was stored in citrate-phosphate-dextrose with adenine (CPDA-1) prior to its use. RBCs were 
separated from plasma and leukocytes by three washings in RPMI 1640 medium. P. falciparum 
laboratory strains Palo Alto, FCB1 and It-G (both mycoplasma-free) were cultivated in RPMI 1640 
medium containing HEPES, supplemented with 20 mM glucose, 2 mM glutamine, 0.025 mM 
adenine and 32 mg/l gentamycin at 2% hematocrit
56,57
. Parasite cultures were synchronized as 
described by Lambros and Vanderberg
58
. It was observed that through this procedure P. falciparum 
cultures maintain synchronicity for 2-3 cycles as already described by Ayi K, et al. 
 
 
 
3.2. Treatment of parasitized/red blood cells 
 
To stimulate HMC formation, RBC and pRBC were suspended at an hematocrit of 30% and 
incubated with different concentrations (0, 0.2, 0.4, 0.8, 1 mM) of Phenylhydrazine at 37 °C for 4 
hours. Also for the same reason were treated with dihydroartemisinin and different Syk inhibitors 
for 12 and 24 hours at 37 °C in the dark. Each reaction was terminated by three washes with PBS-
glucose. For all protocols described, untreated controls were processed identically except that the 
stimulant/inducer was omitted from the incubation. 
 
 
3.3. Drug Susceptibility Assays of Cultured Parasites. 
 
All inhibitors were solubilized in anhydrous DMSO at a 10mM stock concentration and serially 
diluted in anhydrous DMSO prior to addition to malaria cultures. Untreated cultures were run in 
parallel with the same final concentration of DMSO as the drug treated cultures. 24 hours after their 
synchronization (estimated time from the start of the cycle 20-22 hours), cultures and fresh isolates 
of P.falciparum were treated in presence of different concentrations of dihydro-artemisinin (DHA), 
or artesunate at a variable concentrations (from 0.6 to 10 nM) combined with the Syk inhibitors: 
P505-15, R406 (Calbiochem, Darmstadt, Germany), Entospletinib, Syk inhibitor II (from now on 
abbreviated as SYK II),Piceatannol and Imatinib at variable concentrations (from 0.1 to 10 µM). 
 
Experiments were also perfomed treating  Plasmodium cultures with fixed concentrations of (0.05 
47 
to 2 μΜ) R406, SYK II or Imatinib in presence of variable concentrations of DHA (from 0.6 to 10 
nM) combined with mefloquine (MFQ), Piperaquine (PPQ), Lumefantrine (LMF), Amodiaquine 
(AMQ) using each of them at a fixed concentration (1 to 10 nM). 
 
 
 
3.4. Isobologram preparation and Combination index (CI) measurement. 
 
Parasitemia levels of parasite maturation in wells were measured and nonlinear concentration 
response curves of drug A, drug B and all the combinations were made in Microsoft excel. 
Isobolograms were plotted with IC50 concentrations to determine the interaction between drug A, B 
and C. In plot x there is the IC50 concentration of drug A alone and in plot y the IC50 concentration 
of drug B alone. The line of additivity is constructed by connecting these two points. The other 
spots are the IC50 concentrations of the two drugs used in combination. Synergy (CI< 1), additivity 
(C=1), or antagonism (CI>1) are indicated by the combination index theorem of Chow-Talalay 
which is offering a quantitative definition as already described above. 
 
 
 
 
3.5. Assessment of parasitemia by Light Microscopy. 
 
To assess total parasitemia, the share of rings, trophozoites, schizonts and merozoites, and to judge 
on morphology, thin smears were prepared from cultures at indicated times and stained with Diff-
Quick stain (Medion Diagnostics, CH) and at least 2000 cells were examined microscopically by 3 
observers. The experiments were done in triplicate. 
 
 
3.6. IC50 measurement. 
 
To calculate the half maximal inhibitory concentration, that inhibits 50% of malaria parasite (IC50), 
of different Syk inhibitors used as single drugs or in combination with others antimalarial drugs, we 
used ICEstimator software 1.2 version. The program estimates IC50 through nonlinear regression 
using a standard function of the R software. 
 
3.7. Preparation of cells for immunofluorescence (Confocal microscopy) 
 
 
RBCs treated with/without PHZ and pRBCs were pelleted and washed twice in PBS 1× containing 
5 mM glucose and then fixed for 5 min in 0.5% acrolein in PBS. Cells were rinsed three times then 
permeabilized in PBS containing 0.1 M glycine (rinsing buffer) plus 0.1% Triton X-100 for 5 min 
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and again rinsed 3× in rinsing buffer. To ensure complete neutralization of unreacted aldehydes, the 
cells were then incubated in rinsing buffer at room temperature for 30 min. 
 
After incubation, all nonspecific binding was blocked by incubation again for 60 min in blocking 
buffer (PBS containing 0.05 mM glycine, 0.2% fish skin gelatin and 0.05% sodium azide). Staining 
of fixed, permeabilized RBCs was performed by using specific antibodies diluted in blocking 
buffer. After labeling, resuspended RBCs were allowed to attach to coverslips coated with 
polylysine, and the coverslips were mounted by using Aqua-Mount (Lerner Laboratories, New 
Haven, CT). The auto-fluorescence of HMC was visualized by exciting at 488 nm and observing 
their emission in the 630–750 nm range. Samples were imaged with a Bio-Rad MRC1024 (Bio-
Rad) confocal microscope equipped with a 60×1.4 numerical aperture oil immersion lens. 
 
3.8. Electron paramagnetic Resonance (EPR) measurements 
 
 
 
 
The detection of free radicals was carried out using N-tert-Butyl-α-phenylnitrone (PBN) as spin 
trap. 100 µL of PBN (stock solution 1M in DMSO) was added to 50 µL of normal (RBCs) or 
parasitized (pRBCs) red blood cells (hematocrit 10 %) and the volume completed to 300 µL with 
PBS after addition of Dihydroartemisinin (200 µM in DMSO). The solution was then transferred 
into a flat quartz cell (FZKI160-5 X 0.3 mm, Magnettech, Berlin, Germany) for EPR analyses. 
 
EPR spectra were obtained at room temperature using the X-band on a Bruker EMX-8/2.7 (9.86 
GHz) equipped with a gaussmeter (Bruker, Wissembourg, France) and a high-sensitivity cavity 
(4119/HS 0205). WINEPR and SIMFONIA softwares (Bruker, Wissembourg, France) were used 
for EPR data processing and spectrum simulation. Typical scanning parameters were: scan number, 
5; scan rate, 1.2 G/s; modulation frequency, 100 kHz; modulation amplitude, 1 G; microwave 
power, 20 mW; sweep width, 100 G; sweep time, 83.88 s; time constant, 40.96 ms; magnetic field 
3460-3560 G. 
 
3.9. Fluorescence analyses 
 
 
For the detection of intracellular ROS level we used the cell-permeable ROS-sensitive probe 2',7'-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA) which becomes fluorescent upon oxidation. 
The oxidation of H2DCFDA was followed by measuring the fluorescence in 96-well black-walled 
microplates (Corning, Sigma Aldrich) using a SAFAS Xenius (Monaco). 8 µL of the stock 49 
solution (0.5 mM in DMSO) was added to 100 µL of the RBC solutions and the volume was 
completed to 200 µL with PBS after addition of dihydroartemisinin (final concentration 200 µM) 
when needed. 
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4. RESULTS 
 
4.1. Chapter synopsis 
 
This chapter of the results constitutes of three main sections. Firstly, the IC50 concentrations of 
different Syk inhibitors are presented along with currently used antimalarial drugs in different P. 
falciparum strains. Secondly, the effect of Syk inhibitors on artemisinin efficacy is analyzed. In 
that section, six different Syk inhibitors and their combinatory effect on different artemisinin 
derivatives (Dihydroartemisinin, Artesunate and Artemether) are presented by graphical 
presentations (isobolograms) and their combination index values (Chou-Talalay). Finally, as it is 
already known that iron (II) activates artemisinin by producing radicals, we present the 
hypothetical role of HMC [Fe (III)] accumulation by Syk inhibitors to the artemisinin activation. 
 
 
 
4.2. In vitro study of Syk inhibitors in Plasmodium falciparum strains 
 
4.2.1. IC50 values of all tested Syk inhibitors in vitro 
 
 
 
 
In order to investigate the action of different Syk inhibitors (P505-15, R406, Entospletinib, 
Imatinib, SYK II, Piceatannol and SYK IV) on P. falciparum cultures and evaluate their IC50 
concentrations, we measured their activity at varying concentrations (0,05 to 10 μM), durations 
and on different parasite stages in several strains (Palo alto, FCB-1 and It-G). 
 
In Tables 4 and 5 there are the IC50 concentrations of all tested Syk inhibitors after 24 and 48 
hours of incubation. This section also presents the parasitemia levels under different drug 
treatments and their morphological changes in the presence of a specific Syk inhibitor (P505-15) 
on P.falciparum cultures after 24, 48, 72 and 96 hours of treatment. Among all tested strains, the 
most efficient Syk inhibitor appears to be P505-15, as it presents the lowest IC50 concentration 
(both in 24 and 48 hours) needed to eliminate 50% of parasitemia. The IC50 concentration of 
P505-15 was 0.83 μΜ (± 0.06) and 0.49 μΜ (± 0.07) at 24 and 48 hours of incubation 
respectively. 
 
The mentioned data refers to the Palo alto strain as no significant differences have been observed 
 
among the 3 strains regarding their IC50 concentrations. Indeed, P505-15 (Syk IC50 = 1 nM) is a 
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highly selective novel inhibitor of Syk with the lowest IC50 concentration from all the tested Syk 
inhibitors. 
 
Furthermore, R406 appears to be the second most efficient Syk inhibitor regarding its IC50s (2.62 
 
± 0.83, 0.55 ± 0.19) at 24 and 48 hours of treatment respectively. 
 
 
Table 4. In vitro susceptibility (IC50 values) of P. falciparum Palo alto strain after 24 and 48 hours of treatment 
with different Syk inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. In vitro susceptibility (IC50 values) of P. falciparum FCB1 and It-G strain after 24 and 48 hours of 
treatment with different Syk inhibitors. 
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4.2.2. Morphological changes induced by a representative Syk inhibitor 
 
 
Figure 15. shows the morphological changes of parasites induced by the high concentration 
(5μΜ) of a specific Syk inhibitor (P505-15) at different durations of treatment (24, 48, 72 and 96 
hours). Parasites are incapable to accomplish their egress and to finish their life cycle. Indeed, 
after 24 hours of treatment some trophozoites appeared to be out of the erythrocyte, and 
compared to the control cultures, they seemed to be more pyknotic. Finally after the 48 hour 
treatment period, highly shrunken and stained deep purple parasites (presumably dead) became 
noticeable. 
 
 
Figure 15. Morphological changes in Plasmodium falciparum cultures after treatment with a 
specific Syk inhibitor (P505-15) 
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 4.2.3. Effect of P505-15 on inhibition of P.falciparum parasitemia 
 
 
In the third set of experiments, parasitemia was monitored after 24 and 48 hours of treatment in 
presence of different concentrations (0.2 to 5 μΜ) of P505-15 (representative Syk inhibitor). 
After 24 hours of treatment, at the stage of trophozoites with concentrations as low as 1 μM, a 
two-fold decrease in parasitemia was observed. Finally, in presence of a potent concentration (5 
μΜ) the parasitemia dropped five times in comparison with the control. Interestingly, P505-15 
appears to be more potent at 48 hours of treatment (at the ring stage) and almost eliminates all 
parasites when higher concentrations were used. It has to be mentioned that not only P505-15 
shows this effect, but all tested Syk inhibitors have the same behavior regarding the ability to 
completely eliminate parasites after 48 hours of treatment. 
 
 
Figure 16A & B. Parasitemia (%) after 24 and 48 hours of treatment with P505-15  
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4.2.4. In vitro evaluation (IC50 values) of different antimalarial drugs 
 
 
In order to analyze the in vitro combination activity of different Syk inhibitors with already in 
use antimalarials, it was necessary first to test them alone at different concentrations in all the 
mentioned strains, and obtain their IC50 concentrations. In Table 6 all the IC50 concentrations of 
the different antimalarial drugs in Palo alto strain are presented. All ARTs (Dihydroartemisinin, 
Artesunate and Artemether) present IC50 concentrations lower than 3 nM. In agreement with the 
literature data, artemisinin appears in higher IC50 concentrations, as are the tested 
aminoquinolines. No significant differences have been observed among the 3 strains and for this 
reason, we will present the isobolograms only in one strain (Palo alto). 
 
Table 6. IC50 values of different antimalarial drugs in Palo alto strain after 24 hours of treatment  
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4.3. In vitro activity of Syk inhibitors in combination with ARTs 
 
 
In order to analyze the in vitro combination activity of Syk inhibitors on artemisinin efficacy, 
Plasmodium falciparum was treated with different Syk inhibitors and ARTs as described above 
(material and methods). The evaluation of the possible synergism has been done based on the 
method of Chou – Talalay as already described . It is worth noting that synergism is a 
physicochemical mass-action law issue and not a statistical issue, so we determine synergism 
with isobolograms and CI values, rather than P values. Also, the combination index analysis 
provides an easy presentation of quantitative synergy data. IC50 values of dihydroartemisinin, 
artesunate and artemether have been measured at 6, 12, 24 and 48 hours in combination with 
different concentrations (0,05-10 μΜ) of different Syk inhibitors (P505-15, R406, Entospletinib, 
Syk II, Imatinib and Piceatannol. The following, Figures (17-19) and Table 9, show all the 
tested combinations with isobolograms and combination index values. 
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4.3.1. Syk inhibitors in combination with ARTs at 24 hours of incubation 
 
 
4.3.1.1. Syk inhibitors in combination with Dihydroartemisinin (DHA) 
 
 
 
 
Figure 17 shows the isobolograms at 50% effect level, and table 9 summarizes the results. In 
every concentration of each SYK inhibitor combined with DHA, the isobologram analysis 
showed extensive synergy, with the maximum extent of about 5-fold synergy occurring at a 
fairly broad range of concentration ratios. In table 9. there are the concentrations of the Syk 
inhibitors that determine a synergic effect and are included between 50 and 500 nM, determining 
approximately a 2-5 fold decrease of the IC50 of the combined DHA. In particular, table 7 shows 
a fold decrease of the IC50 concentration of DHA, based on the use of different Syk inhibitors 
(250 nM). The highest decrease, 4.8 folds observed with the use of P505-15 and the lower 
decrease observed with the use of Imatinib (1.5 fold decrease). 
 
At the higher Syk inhibitors concentration (500 nM), the CI values were consistently below 1, 
indicating synergy. In general, the plots showed well-spaced concentration points, with several 
data points near the IC50 value. The experimental design used approximately five-fold steps in 
concentration dilution. Furthermore, maximal synergy of approximately 5-fold at 100 nM of 
P505-15 was achieved with a combination index of 0.42. Also, the combination with R406 
appears a CI value of 0.42 (table 9). Indeed, at lower concentrations, all data points were below 
the line of additivity indicating still synergy. CI values decreased at increasing effect levels, 
indicating increasing degree of synergy at higher effect levels. Synergy of greater than 1.5- fold 
at the 50% effect level was observed for all the tested Syk inhibitors. 
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Table 7. Fold decrease of IC50 concentration of DHA in presence of Syk inhibitors (the IC50 concentration of DHA 
alone is 2.64 nM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Isobologram presentation of Dihydroartemisinin (DHA) in combination with different Syk inhibitors 
after 24 hours of treatment 
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4.3.1.2. Syk inhibitors in combination with Artesunate (AS) and Artemether (ATH) 
 
 
 
 
At all concentrations of all Syk inhibitors combined with AS, the isobologram analysis (Fig.18) 
and the CI showed synergy, with the maximum extent of about 2.13-fold synergy. In Table 9 
there are the concentrations of the Syk inhibitors that determine a synergic effect and are 
included between 50 and 500 nM, determining approximately a 1.82- 2.13 fold decrease of the 
IC50 of the combined AS. In particular, Table 8 demonstrates a fold decrease of the IC50 
concentration of AS based on the use of different Syk inhibitors (250 nM). The greatest 
reduction, of 2.13 fold was observed with the use of P505-15, and the lowest decrease observed 
with the use of Imatinib (1.82 fold decrease). 
 
At the higher Syk inhibitors concentrations (500 nM), the CI values were consistently below 1, 
indicating synergy. CI values increased in combination with AS, indicating the decreasing degree 
of synergy in comparison with DHA. Maximal synergy at 250 nM of SYK II was achieved with 
a combination index of 0.55. Finally, one more derivative of artemisinin, ATH, showed nearly 
synergism with all the combined Syk inhibitors. The maximal synergy observed at 250 nM of 
Piceatannol with a CI value of 0.8. In comparison with the other artemisinin derivatives, ATH 
appears the lower CI values (Table 9) and the lower fold decrease (data not shown). 
 
 
 
Table 8. Fold decrease of IC50 concentration of DHA in presence of Syk inhibitors (the IC50 concentration of AS 
alone is 2.45 nM). 
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Figure 18. Isobologram presentation of Artesunate (AS) in combination with different Syk inhibitors after 24 
hours of treatment 
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 4.3.2 Syk inhibitors in combination with ARTs at 48 hours of incubation 
 
 
Finally, regarding 48 hours of incubation of Syk inhibitors and ARTs, the results remain really 
interesting as there is still a noticeable synergy in all concentrations with all Syk inhibitors. In 
figure 19 there are the isobolograms of 3 representative Syk inhibitors (R406, SYK II and 
Imatinib) in combination with DHA and AS. The isobologram analysis presents synergy in all 
conditions determining approximately a 1.5-4 fold decrease of the IC50 of the combinations. In 
general, the plots showed well-spaced concentration points, with several data points near the 
IC50 value. The experimental design used approximately five-fold steps in concentration dilution 
for 24 hours. Furthermore, the maximal synergy of approximately 5-fold at 50 nM of R406 was 
achieved with a combination index of 0.44. Also, the combination with SYK II presented a CI 
value of 0.46 (table 9). Indeed at higher concentrations all data points were below the line of 
additivity, indicating synergy. In general, CI values decreased at decreasing effect levels, 
indicating an increased degree of synergy at lower effect levels. Synergy greater than 1.5- fold at 
the 50% effect level was observed for all the tested Syk inhibitors with all ARTs. 
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 Figure 19. Isobologram presentation of Dihydroartemisinin (DHA) and Artesunate (AS) in combination with 
representative Syk inhibitors (R406, SYK II and Imatinib) after 48 hours of treatment 
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 Table 9. Combination index of Syk inhibitors (P505-15, Entospletinib, R406, SYK II, Imatinib and Piceatannol) 
with ARTs (DHA, AS and ATH) after 24 and 48 hours of incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Αll the presented data evidence marked a synergic interaction after 24 and 48 hours of incubation 
on all tested Syk inhibitors (P505-15, Entospletinib, R406, Syk II, Imatinib and Piceatannol) with 
all the tested ARTs. All the concentrations of Syk inhibitors (50 to 500 nM) have a synergic 
activity with ARTs determining a decrease of their IC50s. This result indicates very different 
mechanisms of action and effects on plasmodium of both Syk inhibitors as single agents, and in 
combination with artemisinins: a) At low concentrations (5-250 nM), Syk inhibitors do not show 
any measurable effect on the growth of the parasite, however when used in combination with 
ARTs, they potentiate the artemisinin activation and inhibit parasite growth; b) the appearance of 
the synergic effect of Syk inhibitors in combination with artemisinins is shown at both 24 and 48 
hours of incubation. 
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 4.3.3 Syk inhibitors in combination with other antimalarial drugs 
 
 
Sets of experiments have been performed in order to identify the possible synergy, or not, of Syk 
inhibitor representatives (R406 and Imatinib) in combination with different in-use antimalarial 
drugs such as mefloquine (MFQ), piperaquine (PPQ), lumefantrine (LMF) and amodiaquine 
(AMQ). In figure 20 and table 10 there are the mentioned isobolograms and their CI values. On 
one hand, the combination of Syk inhibitors with MFQ present slight antagonism as all the points 
are located away from the line of additivity for both imatinib and R406. Indeed almost all the CI 
values are more than 1 indicating additivity or even slight antagonism. On the other hand, PPQ 
and LMF present slight synergy or additivity with CI values for R406 from 0.61 to 1.04 and 0.78 
to 0.92 for imatinib. Finally, regarding the combination with AMQ, the plots showed well-spaced 
concentration points, with several data points near the IC50 value. The maximal synergy of 
approximately 4 fold decrease was observed in combination with imatinib with a CI value at 0.47 
(indicating synergy) (table 9). Synergy greater than 2- fold at the 50% effect level was observed 
for all the tested Syk inhibitors with AMQ. 
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Figure 20. Isobologram presentation of different antimalarial drugs, Mefloquine (MFQ), Lumefantrine (LMF), 
Piperaquine (PPQ) and Amodiaquine (AMQ) in combination with representative Syk inhibitors (R406, and 
Imatinib) after 24 hours of treatment. 
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 4.3.4 Triple combinations (DHA + Imatinib + other antimalarial drugs) 
 
 
A fixed concentration (10 nM) of the anti-malarial drugs MFQ, PPQ, LMF and AMQ (A to D 
respectively), that are currently combined to artemisinins in ACT, have been added to the 
synergistic combination of DHA with Imatinib (representative Syk inhibitor). In the case of the 
following isobolograms in figure21 (A to D), in plot x there is the IC50 concentration of DHA in 
combination with MFQ, PPQ, LMF and AMQ respectively (A-D) and in plot y there is the IC50 
concentration of Imatinib. Those drugs were used at 10 nM concentration that corresponds to 
approximately 30-50% of their IC50. The results contained in the isobolograms (Fig.21) present 
that sub-therapeutic concentrations of those drugs enhance the synergic effect of Syk inhibitors 
on artemisinins. Indeed, all the IC50 concentrations are below the line of additivity indicating 
synergy between them. It should be noticed that even at low concentrations of Imatinib there is 
synergy with all the tested antimalarials. 
 
 
Figure 21. Isobologram presentation of triple combination with fix concentration (10 nM) of MFQ, PPQ, LMF 
 
and AMQ (A-D respectively) with DHA and a representative syk inhibitor (Imatinib).  
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 4.3.4.1 Cumulative drug effect in triple combinations 
 
 
In this set of experiments, the cumulative effect of the triple combination is evaluated after repeated 
administrations every 24 hours with the following compounds: DHA (1 and 2,5 nM) in 
combination with fix concentrations of Imatinib (500 nM) and PPQ (10 nM). When pRBCs were 
treated with the triple combination the parasitemia decreased 1.6 folds compared to DHA (2,5 nM) 
alone. After the second administration a 7.2 and 25 fold reduction of parasitemia was seen. As the 
concentration of DHA was decreased to 1 nM, following the first administration parasitemia 
decreased 1.5 fold and then by 2.2 folds after the second. Finally the last administration saw only a 
2.5 fold reduction, indicating the need of higher DHA concentrations to provide more effective 
synergy (Fig.22). The addition of Imatinib and PPQ enhance the action of DHA, when compared as 
a single agent. Indeed, the triple administration produces effects that are more pronounced than 
those produced by the first dose. 
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 Figure 22. Cumulative drug effect of DHA (1 and 2,5 nM) as a single agent and also with fix concentrations of PPQ 
(10 nM) and Imatinib (500 nM) after three administrations every 24 hours. 
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 4.3.5 Morphological changes of P.falciparum induced by Syk inhibitors in combination with DHA 
 
 
In this embodiment (Fig.23), synchronized cultures were treated with DHA as a single agent and in 
combination with two representative Syk inhibitors (R406 and P505-15). Selected pRBCs were 
presented after 6, 12 and 24 hours of treatment. The most striking morphological alterations were 
observed in fixed blood smears of parasite culture treated with both Syk inhibitors in combination 
with DHA after 24 hours, in comparison to the control cultures. A modest reduction in their size was 
observed at 6 hours of incubation, perhaps suggesting slower parasite growth (i.e. cell cycle delay). 
At 12 hours of incubation, there was evidence of a marked reduction in parasitic growth (i.e. smaller 
size). Irregularly shaped and pyknotic (highly shrunken and stained deep purple) parasites 
(presumably dead) were finally observed at the last time-point (24 hours). On the other hand, DHA 
treated parasites did not present similar morphological changes at the various time points. 
 
 
Figure 23. Parasite morphology after 6, 12 and 24 hours of drug treatment. Plasmodium falciparum Palo alto parasite 
cultures were incubated with 1,25 nM DHA as a single agent or in combination with representative Syk inhibitors (R406 
and P505-15). Giemsa-stained thin blood smears were prepared from drug-exposed and solvent control cultures and 
viewed by bright-field light microscopy using a 100x oil-immersion objective. In each case, two representative images of 
damaged parasites are shown. 
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4.3.6 Stage-dependent activity of R406 in combination with DHA 
 
 
In the last set of experiments, we measured the stage-dependent activity of a representative Syk 
inhibitor (R406) in combination with DHA. Figure 24 shows the stage-dependent activity of 
pRBCs in presence of R406 (250 nM) in combination with DHA (2 nM) at different stages of 
parasite development. The maximal activity was observed between 12 and 40 hours post-infection 
which corresponds to the parasite’s intraerythrocytic stages. This indicates that a long-term 
inhibition of R406 in combination with DHA markedly affects the capability of the parasite to 
complete its growth cycle and potentiate the activity of DHA. 
 
Figure 24. Stage-dependent sensitivity of parasites to a fixed dosage of R406-DHA. Relative activity of R406-DHA 
(250 nM + 2nM) added at 6, 12, 24, 36, 40 and 48 hours post infection. Values are expressed as a percentage of the 
maximal R406-DHA activity (treatment time 24 hours post infection) measured as % activity. The data is an average of 
5 experiments ±SD. 
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4.4  Role of hemichromes on artemisinin activation 
 
 
4.4.1 Effect of Syk inhibitors on hemichromes (HMC) accumulation 
 
 
 
 
Ferrous iron and heme are known to be necessary for the activation of artemisinin in parasitized 
RBCs and its subsequent anti-malarial action. It has also been demonstrated that Syk inhibitors 
block the efflux of denatured hemoglobin products (hemichromes) from erythrocytes treated 
with oxidant agents. In order to define the mechanism of action which explains the synergic 
effect of Syk inhibitors on ARTs, we investigated their effect on the accumulation of denatured 
hemoglobin (HMC) in parasitized erythrocytes. The accumulation of HMC bound to the host cell 
has been measured in presence of DHA and P505-15 after 12 and 24 hours of treatment. It is 
worth noting that the accumulation of HMC is notable 3 hours after treatment with R406 that is 
coherent with the time needed to observe the synergic effect of Syk inhibitors on DHA. 
 
Figure 25 shows that R406 induced the accumulation of HMC in pRBCs starting from 3 hours 
of incubation until the following 24 hours of treatment. To better visualize HMC accumulation, 
we treated normal RBCs and pRBCs with 1 mM of PHZ to induce the formation of HMC 
through the specific oxidation of hemoglobin and then we observed them with Confocal 
microscopy (Fig. 26). HMC formation in RBCs and pRBCs are visible in figures 26B and 26E 
after the treatment with PHZ. Figure 26D confirms the formation of HMC after the treatment of 
pRBCs with R406. 
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 Figure 25. Hemichromes accumulation after 3,6,12 and 24 hours of incubation in parasitized RBCs treated with 
DHA (0.5 nM) and /or R406 (0.5 μΜ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Confocal Images of HMC contained in pRBCs treated 12 hours with R406 (0,5μΜ) (C) and 4 hours 
with PHZ (1mM) (D). HMC were visualized by their auto-fluorescence at 488 nm (excitation) / 630-750 nm 
range (emission). Images were acquired using the same magnification with a Leica TCS SP5 X (Leica 
Microsystems, Germany) confocal microscope equipped with a 6061.4 numerical aperture oil immersion lens. 
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4.4.2 Free radical production in RBCs treated with PHZ and DHA 
 
 
 
To analyze the effect of hemichromes upon the artemisinin 
activation we first measured the production of ROS using 
EPR associated with the spin trapping method. The spin 
trap used was PBN (α-phenyl-N-tert-butylnitrone) which 
allows , whereas it’s not the case for DMPO, intracellular 
radicals to be trapped due to its greater lipophilicity. The 
corresponding spectra are presented in Figure 28. The 
spectra recorded for hRBCs (RBCs with hemichromes) 
after adding 200 µM Dihydroartemisinin clearly 
demonstrated the apparition of the six-lined spectrum 
characteristic of the PBN-adduct formed after radicals 
trapping (Fig.28d). Simulation yielded to the following 
 
parameters: g= 2.0059; aN=14.9 G; aH = 3.3 G indicating that the hydroxyl radical was formed 
and transformed into 
●
CH3 radicals after reaction with DMSO before trapping. 
 
Figure 28. : EPR spectra (arbitrary unit) recorded with PBN 50 mM for a) RBCs, b) RBCs + DHA 
(200µM), c) hRBCs, d) hRBCs + DHA (200µM). 
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Figure 27. pRBCs with PBN in flat cell 
before EPR reaction 
 
 
 
To confirm these results the same experiments were performed using the fluorescent probe CM-
H2DCFDA, a cell-permeable indicator for the formation of ROS. The incubation of RBCs with 
increasing concentrations of phenylhydrazine caused a parallel rise of all parameters measured. 
To support the hypothesis that HMC promote the activation of DHA, we treated RBCs with 
different concentrations of PHZ for 4 hours in order to have different concentrations of HMC. 
 
Figure 29 shows that in presence of a fix concentration of DHA (200 μΜ) as higher as the 
concentration of HMC is, the higher the production of ROS is. More specific, RBCs containing 
the higher concentration of HMC present the higher increase of ROS production. Indeed, figure 
29 shows a strong correlation (R: 0.95) between the ROS production and hemichromes 
accumulation in RBCs. To better understand the role of HMC we treated RBCs with the higher 
concentration of PHZ (1 mM) to induce the formation of HMC in presence of different 
concentrations of DHA (10 – 200 μΜ). Figure 30 shows that as higher as the concentration of 
DHA (10 μΜ- 200 μΜ) is, the higher the production of ROS is. 
 
Figure 29. HMC accumulation and ROS production using the fluorescent probe H2DCFDA in RBCs treated 
with DHA (200 μΜ) and different concentrations (200-1000 μΜ) of Phenylhydrazine (PHZ) 
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 Figure 30. ROS production using the fluorescent probe H2DCFDA in RBCs treated with fix concentration of 
PHZ (1 mM) and different concentrations (10-200 μΜ) of DHA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.3 Free radical production in pRBCs treated with DHA and Syk inhibitors 
 
 
In this set of experiments in order to analyze the effect of HMC in pRBCs upon the artemisinin 
activation, we treated pRBCs with Syk inhibitors (R406 or Imatinib) to induce the accumulation 
of HMC as already described. We measured the production of ROS using EPR associated with 
the spin trapping method. The corresponding spectra are presented in Figure 31. Firstly, we 
recorded spectra for pRBCs (Fig.31b) without any treatment and then with the addition of DHA 
(200 µM). The addition of DHA clearly demonstrates the apparition of the six-lined spectrum 
characteristic of the PBN-adduct formed after radicals trapping (Fig.31c). The same experiments 
carried out after 24 hours incubation of pRBCs with R406 and the addition of DHA (200 μΜ) 
that increased the intensity of the peak by 12% (Fig.31d). 
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Figure 31. : EPR spectra (arbitrary unit) recorded with PBN 50 mM for a) pRBCs [Rings/Troph.], b) pRBCs 
[Rings] + DHA (200µM), c) pRBCs [Troph.] + DHA, d) pRBCs [Troph.] (treated with Syk inhibitors) + DHA 
(200µM). 
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4.4.4 Effect of iron chelators to the production of radicals 
 
 
The activation of artemisinin has been previously described to be inhibited by iron chelators such 
as deferoxamine
59
. In the present experiment, we have observed that at 400 μM οf DFX 
completely abolishes the ROS production (Fig.32 and 33). Figure 32 shows the decrease of 
ROS production in RBCs treated with PHZ at different concentrations of DFX (100- 400 μΜ). 
At the same time, the same result observed at pRBCs treated with Syk inhibitors (Fig.33). This 
observation strongly indicates that the activation of artemisinins induced by Syk inhibitors is due 
to the accumulation of accessible iron bound to hemichromes. These data provide further 
evidence for the importance of the iron pool in the mechanism of action of artemisinin even as 
ferric ions. 
 
 
Figure 32. Intensity of EPR spectra (arbitrary unit) recorded with PBN 50 mM for a) hRBCs treated with a 
stable concentration of DHA (200 μΜ) b, c, d, e) with different concentrations (100-400 μΜ) of Deferasirox 
(DFX) respectively. 
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Figure 33. Intensity of EPR spectra (arbitrary unit) recorded with PBN 50 mM for pRBCs un/treated with R406 for 
24 hours in combination with a fix concentration of DHA (200 μΜ) and with different concentrations (100-400 μΜ) 
of Deferasirox (DFX). Inlet: example of EPR spectra recorded for pRBC ± deferasirox (400 µM). 
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5 DISCUSSION 
 
 
Most current antimalarial drugs are combinations of an artemisinin plus a ‘partner’ drug from 
another class and are known as artemisinin-based combination therapies (ACTs). They are the 
frontline drugs in treating human malaria infections
20
. They also have a public-health role as an 
essential component of recent, comprehensive scale-ups of malaria interventions and containment 
efforts conceived as part of long-term malaria elimination efforts. Recent reports have shown that 
resistance has arisen to artemisinins which has caused considerable concern and the need to produce 
new antimalarials
28,29
. It has been demonstrated that SYK inhibition in erythrocyte membrane 
suppresses both band 3 phosphorylation and its loss, contextually it also suppresses the capability of 
the parasites to complete their life cycle and infect new erythrocytes. Syk inhibitors are a new 
promising class of antimalarials that have an entirely different mechanism of action from all the 
curently used antimalarials. Syk inhibitors are slow-acting and it will be an advantage if 
administered in association with a fast-acting antimalarial drug such as an artemisinin derivative, 
allowing for both a rapid and prolonged anti-plasmodial activity. 
 
The purpose of this work was to investigate the in vitro combination activity of Syk inhibitors with 
ARTs
53
. Different Syk inhibitors (P505-15, R406, SYK II, SYK IV, Piceatannol, Entospletinib and 
Imatinib) have been tested in combination with different ARTs and quinolines in P.falciparum 
infected RBCs. Syk inhibitors, in combination with a set of artemisinin derivatives widely used for 
the treatment of malaria, exert a marked synergic effect on the growth inhibition of P.falciparum by 
a novel mechanism of action. Supporting their therapeutic utilization it should be noticed that all the 
tested Syk inhibitors caused a 3-5 fold increase in the efficacy of artemisinins for the 50-500 nM 
concentration range. 
 
Interestingly, this range of concentrations is than plasma concentrations measured in subjects 
treated with well-tolerated dosages of Syk inhibitors for other diseases. In order to define the 
mechanism of action to explain the synergic effect of Syk inhibitors on ARTs, we investigated their 
effect on the accumulation of denatured hemoglobin (HMC) in parasitized erythrocytes. 
Hemichromes bound to the host cell membrane and the augmentation of dihydroartemisinin (DHA) 
anti-plasmodial activity has been measured in presence of increasing concentrations of Syk 
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inhibitors. A strong correlation exists (R: 0.96) between ROS production from the activation of 
DHA and hemichrome accumulation at fix concentrations of the Syk inhibitor. In favor of a causal 
relationship between hemichromes accumulation and DHA activation it should be noted that both 
phenomena become evident at the concentration of 500 nM for R406. The accumulation of 
hemichromes is measurable 3 hours after treatment with R406, this result is also coherent with the 
time needed to observe the synergic effect of Syk inhibitors on DHA. 
 
The activation of artemisinin has been previously described to be inhibited by iron chelators such as 
DFX. In the present study we have observed that at a concentration of 400 μM, DFX completely 
abolishes the synergic effect of Syk inhibitors on artemisinins. This observation strongly indicated 
that the activation of artemisinins induced by Syk inhibitors is due to the accumulation of accessible 
iron and or heme bound to hemichromes. Indeed, these data provide further evidence for the 
importance of the iron pool in the mechanism of action of artemisinin, even as ferric ions. The 
mechanism of action is based on the reductive cleavage of the endoperoxide bridge by ferrous 
complexes to form highly reactive O-centered radicals, then C-centered radicals after self-
arrangement. This activation depends on Hb uptake and digestion. During the hemoglobin digestion 
process, four equivalents of [Fe
II
-heme] are released and oxidized into hematin (Fe
III
). This is 
detoxified by the parasite into hemozoin, a highly insoluble microcrystalline form of Fe
III
 
(protoporphyrinIX), however a significant quantity escapes polymerization. This free hematin may 
be responsible for the activation of artemisinin after reduction into Fe
II
 (artemisinin being 
insensitive to FeCl
3
 or hemichromes in absence of RBC)
25,60
. 
 
Hence, an accumulation of Fe
III
 via collection of hemichromes induced by Syk inhibitors would 
potentiate the artemisinin activity. In conclusion, considering their demonstrated tolerability, Syk 
inhibitors represent a new class of antimalarial drugs that possess a unique mechanism of action on 
a non-parasite target; they are also less likely to produce resistant strains and may therefore 
represent a strategic partner drug for ARTs for counteracting artemisinin resistance. 
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6 CONCLUSIONS AND PERSPECTIVES 
 
 
 
 
In conclusion, Syk inhibitors enhance artemisinins anti-plasmodial activity leading to a 5 fold 
decrease of their IC50 values by increasing their efficacy in lower concentrations. Syk inhibitors 
cause a large accumulation of hemichromes in the parasitized erythrocytes triggering the activation 
of artemisinins by producing high amounts of ROS and disturbing the mitochondrial functions of 
parasites leading to their death. Therefore, an accumulation of Fe
III
 via accumulation of 
hemichromes induced by Syk inhibitors, potentiate the artemisinin activity. 
 
Also, considering the results obtained in vitro at all Syk inhibitors concentrations (50-500 nM), the 
CI values were consistently below 1, indicating synergy. Interestingly, no other compounds 
associated to ARTs exist that exert this degree of synergy. The concentrations of Syk inhibitors 
needed to synergize artemisinins is 5-20 fold lower than the IC50 measured to cause a direct effect 
on parasite growth. Such concentrations correspond to very well tolerated dosages and can be 
rapidly reached after oral administration. 
 
Furthermore, Syk inhibitors exert an in vitro synergic activity when used in combination with the 
most widely used ACTs. Such combinations include DHA with PPQ (commercial name Artecan®), 
and ATH with LMF (commercial name Coartem®). 
 
In addition, taking into consideration that Syk inhibitors are acting on the host cell membrane 
instead of the parasite, theoretically this should not lead to the selection of resistant strains and may 
therefore represent a strategic partner drug for counteracting artemisinin resistance. 
 
In the light of these results our future plan will be the conduction of clinical trials in order to test the 
efficacy of Syk inhibitors (Imatinib) in combination with the most widely used ACTs on malaria 
patients. 
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